| Biotech Co (Country/ Symbol) | Pharma Co (Country/ Symbol) | Type/ Product Area | Amount (M) | Terms/Details (Month) |
| 3-Dimensional Pharmaceuticals Inc. (DDDP) | DuPont Pharmaceuticals Co. (unit of E.I. DuPont de Nemours & Co.; NYSE:DD) | Research collaboration/target discovery and use of 3DP s DirectedDiversity technology to generate combinatorial chemistry libraries for drug discovery | $9 | 3DP will generate custom libraries and optimize them to obtain preclinical candidates; for the initial target, 3DP will receive up to $9M, including an up-front technology access fee, R&D funding and milestones; 3DP also will receive royalties on any sales and will be eligible to receive additional payments if more than one target is selected; additional agreement provides DuPont a nonexclusive license to DirectedDiversity to support internal projects; DuPont will pay an annual site license fee for each facility using the technology (2/00) |
| 3-Dimensional Pharmaceuticals Inc. (DDDP) | Boehringer Ingelheim Pharmaceuticals Inc. (unit of Boehringer Ingelheim International GmbH; Germany) | Research collaboration/use of 3DP s DirectedDiversity combinatorial chemistry to discover and refine compounds active against BI targets | ND | 3DP will receive an up-front technology access fee, R&D funding, milestones and royalties on each target selected; BI is responsible for preclinical and clinical development (3/00) |
| 3-Dimensional Pharmaceuticals Inc. (DDDP) | Bristol-Myers Squibb Co. (NYSE:BMY) | Development agreement/applies 3DP's proprietary technologies to discover, refine and develop novel, small-molecule pharma ceuticals directed to genebased biological targets identified by Bristol-Myers | $37.90 | 3DP will receive up-front licensing and technology access fees amounting to $23.5M and committed research funding of $14.4M over the first three years, as well as payments for the purchase of an undisclosed number of ThermoFluor high-throughput screening workstations; Bristol-Myers will receive exclusive worldwide rights to compounds discovered or developed through the collaboration, access to 3DP's proprietary DiscoverWorks technology platform and nonexclusive licenses for patented applications involving 3DP s DirectedDiversity combinatorial chemistry and chemi-informatics, ThermoFlour high-throughput screening and Protein Expression refolding technology; Bristol-Myers will become the first subscriber to 3DP s Proteomica G protein-coupled receptor structural genomics database (7/00) |
| Abgenix Inc. (ABGX) | Abbott Laboratories (NYSE:ABT) | Research and license collaboration/use of Abgenix s XenoMouse technology to generate fully human antiibodies to several disease targets for Abbott | ND | Abgenix could receive research, license fees and milestone payments, plus royalty payments on future product sales by Abbott (5/00) |
| Abgenix Inc. (ABGX) | SmithKline Beecham plc (UK; NYSE:SBH) | Research collaboration/use of Abgenix s XenoMouse technology to generate fully human monoclonal antibodies to an undisclosed target | ND | Abgenix will receive a research license payment and could receive additional fees and milestone payments, plus royalties on future product sales by SB (5/00) |
| Acadia Pharmaceuticals Inc. | Parexel International Corp. | Collaborative agreement/pharmacogenomic services | ND | Parexel will assist clients developing neuropsychiatric products in using Acadia s functional genomics platform to streamline the clinical development process for central nervous system compounds (11/00) |
| Adenosine Therapeutics LLC | DuPont Pharmaceuticals Co. (NYSE:DD) | License agreement/coronary vasodilator compounds, ATL-146e and ATL-193 | ND | DuPont gains worldwide rights to develop and use the compounds within the heart imaging field for diagnosis and prognosis of coronary artery disease, while Adenosine retains rights in all other fields; DuPont will pay a licensing fee and milestones, provide funding for a three-year research program, and will pay royalties on any resulting products; DuPont will also fund clinical trials and license the data to Adenosine for use in clinical trials in other indications (4/00) |
| Admetric BioChem Inc. | SmithKline Beecham Pharmaceuticals | Agreement for the development and evaluation of Admetric s technology to profile and prioritize compounds for drugs | ND | Admetrix will provide the ADMET properties of up to 125 SmithKline compounds; the data will then become part of the MAF database; Admetrix has granted SmithKline an option to negotiate a long-term agreement for access to Admetrix s technology and database; S.R. One Ltd. led the initial venture capital investment (11/00) |
| Adolor Corp. (ADLR) | Santen Pharmaceutical Co. Ltd. (Japan) | License and development agreement/topical uses of ADL 2-1294 (loperamide) for the treatment of ophthalmic pain | ND | Adolor will receive an up-front payment and may receive milestones and royalties on net sales; the companies have agreed to negotiate an agreement for Adolor to market and sell ADL 2-1294 to hospitals in the U.S.; Santen will be responsible for all development activities (4/00) |
| Affymetrix Inc. (AFFX) | The Procter & Gamble Co. (NYSE:PG) | Technology access/P&G will gain broad access to Affymetrix s standard and custom GeneChip arrays, instrumentation and software to monitor gene expression for use in research and development activities; P&G affiliates also have the option to access the technology on the same terms | ND | P&G has preferred access to both standard and custom products under EasyAccess Silver Agreement (5/00) |
| Affymetrix Inc. (AFFX) | Janssen Research Foundation and the R.W. Johnson Pharmaceutical Research Institute (units of Johnson & Johnson; NYSE:JNJ) | Technology access and license/J&J entities gain broad access to standard and custom GeneChip arrays, instrumentation and expression for use in pharmaceutical research and development activities | ND | Access is provided under EasyAccess Silver agreement terms; JRF and PRI also obtained a license to produce and use nucleic acid arrays for gene-expression monitoring as part of internal research efforts (7/00) |
| Affymetrix Inc. (AFFX) | Takara Shuzo Co. Ltd. (Japan) | License agreement/Takara gains a nonexclusive worldwide license under Affymetrix s intellectual property covering lowand medium-density DNA arrays | ND | Affymetrix will receive undisclosed upfront fees and ongoing royalty payments on products sold by Takara; license covers technology used in Takara s IntelliGene DNA chips (9/00) |
| Alkermes Inc. (ALKS) | Ares-Serono Group (Switzerland) | Research collaboration/development of extended-release version of an undisclosed AresSerono therapeutic protein | $30 | Ares-Serono gains exclusive worldwide rights to products resulting from the deal, and will provide development funding, milestones that could exceed $30M, plus royalties based on sales; Alkermes is expected to manufacture products; Ares-Serono will handle clinical trials, approvals and marketing (1/00) |
| Alkermes Inc. (ALKS) | Eli Lilly and Co. (NYSE:LLY) | License agreement and research and development collaboration/inhaled formulation of human growth hormone based on Alkermes AIR pulmonary drug delivery system | ND | Agreement follows successful completion of nine-month feasibility program conducted by the two companies; Alkermes will receive up-front fees, research funding and milestones, plus royalties on any sales; Lilly receives exclusive worldwide rights and will be responsible for clinical trials, regulatory approvals and marketing on a worldwide basis (2/00) |
| Alkermes Inc. (ALKS) | Glaxo Wellcome plc (UK; NYSE:GLX) | License agreement and research and development collaboration/use of Alkermes AIR pulmonary drug delivery technology for multiple product candidates in respiratory diseases | ND | Glaxo receives exclusive worldwide rights to products in up to four undisclosed respiratory disease categories, and will provide development funding and milestones, as well as royalties on product sales; each company will have manufacturing rights and obligations; Glaxo is responsible for clinical trials, regulatory approvals and marketing (2/00) |
| Alkermes Inc. (ALKS) | Glaxo Wellcome plc (UK; NYSE:GLX) | License/use of Alkermes' AIR technology for pulmonary drug delivery of multiple product candidates in four respiratory disease therapeutic categories | ND | Glaxo gains exclusive worldwide rights to products resulting from the collaboration and will provide Alkermes with development funding, milestone payments and royalties on sales; each company will have manufacturing rights and obligations, and Glaxo is responsible for clinical trials, regulatory approvals and marketing; Glaxo will make an equity purchase of Alkermes common stock (6/00) |
| AltaRex Corp. (Canada; TSE:AXO; OTC BB:ALRXF) | Dompe Farmaceutici SpA (Italy) | Memorandum of understanding to form an alliance for OvaRex MAb | $5 | The memorandum gives Dompe the rights of first offer for additional cancer antibodies in Italy, Spain, Portugal, Switzerland, AusAustria and certain Eastern European countries; Dompe has escrowed $5M to purchase AltaRex common shares through a private placement; Dompe has the option to purchase an additional $5M in equity and will pay up to $1.25M upon OvaRex MAb commercialization in Spain and Portugal (11/00) |
| Altea Genomics Inc. | Elan Corp. plc (Ireland; NYSE:ELN) | Agreement to form a joint venture company to develop up to five products using Altea s noninvasive MicroPor technology and Elan s formulation technology | ND | The new joint venture company will develop up to five products, focusing on DNA delivery; products under consideration include DNA vaccines against infectious diseases and cancer (8/00) |
| Ambion Inc. | Abbott Laboratories (NYSE:ABT) | License agreement/use of armored RNA tech nology in products and processes for in vitro diagnostics (4/00) | ND | Abbott gains nonexclusive worldwide rights (4/00) |
| American Biogenetic Sciences Inc. (OTC BB:MABA) | Abbott Laboratories (NYSE:ABT) | License agreement/ABS neurological compound ABS-103 (derivative of epilepsy drug valproate) | ND | Abbott gains exclusive worldwide rights to develop and market the compound, and will make an up-front equity investment as well as additional milestone payments (1/00) |
| Amersham Pharmacia Biotech Inc. (jointly owned by Nycomed Amersham plc; UK; NYSE:NYE; and Pharmacia Corp.; NYSE: PHA) | Novo Nordisk A/S (Denmark) | Technology agreement/use of Amersham's microarray technology for re search into disease and development of drugs | ND | Novo gains rights to use AP Biotech technology to make and use gene expression microarrays (4/00) |
| Amersham Pharmacia Biotech Inc. | The Procter & Gamble Co. (NYSE:PG) | License/develop a chemistry to expand percentage of proteins and peptides that can be identified using the Ettan MALDI-Tof mass spectrometry analysis system | ND | Worldwide license covers a novel chemistry developed by P&G called Peptide Derivatization Technology (12/00) |
| Amrad Corp. Ltd. (Australia) | Ares-Serono Group (Switzerland) | License agreement and research collaboration/recombinant leukemia inhibitory factor for use in the field of reproductive health | $16 | Ares-Serono made an undisclosed up-front payment and will pay milestones of up to $16M, plus royalties on any product sales; AMRAD is developing the protein for neuromuscular diseases under the name AM424 (1/00) |
| Anadys Pharmaceuticals Inc. | Pharmacia Corp. (NYSE:PHA) | Collaborative and license agreement/Pharmacia gains a nonexclusive license to use Anadys GATE technology, for use in discovery and target validation for antifungals | ND | Anadys will collaborate for the transfer of the technology; Anadys will receive technology licensing fees and research payments; specific financial terms were ND (8/00) |
| Applied Biosystems Group (NYSE:ABI) | Millipore Corp. (NYSE:MIL) | Collaboration/develop and market next-generation sample preparation consumables for highthroughput proteomics | ND | Financial details were ND (12/00) |
| Arakis Ltd. | Penwest Pharmaceuticals Co. | Joint development agreement for AD 121 | ND | The companies will jointly develop the compound and share equally in commercialization profits (11/00) |
| Arena Pharmaceuticals Inc. (ARNA) | Fujisawa Pharmaceutical Co. Ltd. (Japan) | Research collaboration/validation of orphan G protein-coupled receptors (GPCRs) as drug screening targets; use of Arena s CART technology to identify modulators of GPCRs in a ligand-independent manner | ND | Joint validatation of selected GPCR targets; Arena will be responsible for receptor identification and regulation, application of its CART technology to Fujisawa-selected receptors and validation of screening assays based upon selected receptors; Fujisawa will screen its compound library using CART receptor assays and will handle preclinical and clinical development of leads; agreement includes an opportunity for Arena to screen selected receptors using its in-house library; Arena will receive assay license, milestone and potential royalty payments (1/00) |
| Arena Pharmaceuticals Inc. (ARNA) | Eli Lilly and Co. (NYSE:LLY) | Research collaboration/development of orphan G protein-coupled recept ors as drug screening targets, using Arena's CART technology; initial focus on central nervous system, endocrinology and cardiovascular targets | ND | Arena will be responsible for receptor identification, localization and regulation, and application of CART technology to Lillyselected receptors and validation of screening assays based on those receptors; Arena will receive an up-front fee, research funding, milestones and royalties on resulting products; Lilly will be responsible for screening its chemical compound library using selected CART receptor library, identification of chemical leads and preclinical and clinical development; Lilly has exclusive worldwide rights to any resulting products (4/00) |
| Argonex Inc. | Wyeth-Lederle Vaccines (unit of American Home Products Corp.; NYSE:AHP) | Research collaboration/identification of antigens associated with Chlamydia pneumoniae for development of potential vaccines | ND | Argonex will use its antigen technology to isolate, identify and sequence peptides uniquely expressed on cells infected with C. pneunomiae; Wyeth-Lederle will evaluate peptides for potential use in vaccine development; Argonex will receive research funding and potential royalties (2/00) |
| Aronex Pharmaceuticals Inc. (ARNX) | Sumitomo Pharmaceuticals Co. Ltd. (Japan) | License/exclusive rights in the U.S. to a particular class of DACH platinum compounds | $0.50 | Sumitomo will receive a $500,000 up-front payment, milestone payments and royalties based on sales of Aroplatin in the U.S. (12/00) |
| ArQule Inc. (ARQL) | SmithKline Beecham plc (UK; NYSE:SBH) | Drug discovery collaboration to identify, optimize and deliver clinical candidates | ND | ArQule will optimize lead compounds in at least two programs, the first compound identified by SmithKline and the second identified from the Compass Array library; agreement includes research and development payments, milestone payments and royalties (11/00) |
| Array BioPharma Inc. (ARQL) | Asahi Chemical Industry Co. Ltd. | Research collaboration/access to Array s smallmolecule libraries | ND | Asahi gains access to Array s libraries on a semi-exclusive basis (3/00) |
| Array BioPharma Inc. (ARQL) | Eli Lilly and Co. (NYSE:LLY) | Research collaboration/chemistry-based collaboration for drug discovery | ND | Up to 30 Array scientists will work with Lilly scientists on several drug discovery projects (3/00) |
| Artemis Pharmaceuticals GmbH (Germany) | Bayer AG (Germany) | Research collaboration/use of Artemis technology to develop methods for toxicology testing of pharmaceutical and crop protection compounds | ND | ND (2/00) |
| Astex Technology Ltd. (UK) | Janssen Research Foundation (unit of Johnson & Johnson; NYSE:JNJ) | Research collaboration/use of Astex's high throughput X-ray crystallography technology to optimize lead compounds in drug discovery | ND | ND (4/00) |
| AtrixLaboratories Inc. (ATRX) | Pfizer Inc. (NYSE:PFE) | Research and license agreement/Pfizer gains access to Atrix s paranteral, transmucosal and topical drug-delivery systems for new product | $5 | Pfizer made an initial $5M investment in Atrix; Pfizer will fund development and commercialization and has rights to market resulting products; Atrix retains manufacturing rights and will receive royalties on product sales (8/00) |
| AtrixLaboratories Inc. (ATRX) | Geneva Pharmaceuticals Inc. (member of the Novartis AG group) | Collaboration agreement to develop and manufacture prescription generic dermatology products | ND | Alliance has targeted a number of products to develop over a 10-year period; Geneva will market the products developed by Atrix under a profit-sharing agreement (10/00) |
| atugen AG (Germany) | Boehringer Ingelheim International GmbH (Germany) | Research collaboration/use of atugen's gene target validation services | ND | BI will provide Atugen with gene target sequences and specific cell lines; Atugen will provide delivery optimization to the cell lines and develop GeneBloc reagents to inhibit the expression of the target genes (4/00) |
| Atugen AG (Germany) | F. HoffmannLa Roche Ltd. (Switzerland) | Research collaboration/use of Atugen's GeneBloc technology to study gene function in vivo | ND | atugen will identify gene-expression inhibitors (GeneBlocs) in cell-based assays, and Roche will utilize the GeneBlocs for in vivo applications (6/00) |
| Atugen AG (Germany) | Bayer AG (Germany) | Research collaboration/Bayer provides gene target sequences and cell lines for cell delivery optimization by atugen and subsequently produce Gene Bloc reagents to inhibit target gene expression | ND | ND (9/00) |
| Aurora Biosciences Corp. (ABSC) | NV Organon (the Netherlands) | Development collaboration/development of high-throughput drug screening assays, including orphan G proteincoupled receptors, ion channels and enzymes; Organon gains access to Aurora's ion channel technology platform | ND | Aurora will receive an up-front and annual payments for screen development and technology access; Organon will also make milestone and royalty payments for compounds commercialized through the use of the screens; Organon has an option to have Aurora perform screening on Aurora's ultrahigh-throughput screening platform (UHTSS) (4/00) |
| Aurora Biosciences Corp. (ABSC) | Wyeth-Ayerst Research (unit of American Home Products Corp.;NYSE:AHP) | License agreement/Aurora's green fluorescent protein (GFP) mutant technology | ND | Wyeth gains a nonexclusive license to GFP technology internal use in specified genomics technologies and other applications, including use in transgenic organisms (4/00) |
| Aurora Biosciences Corp. (ABSC) | The R.W. Johnson Pharmaceutical Research Institute and Janssen Research Foundation (units of Johnson & Johnson; NYSE:JNJ) | Development agreement/ion channel assay development and access to Aurora technologies and scientific support | ND | ND (5/00) |
| Aurora Biosciences Corp. (ABSC) | Merck & Co. Inc. (NYSE:MRK) | Development agreement/Merck will provide an ion channel target and selected compound library for a target assay development using Aurora s voltage sensor probe technology | ND | Aurora will receive research payments, research and development milestones and royalties on marketed products that are based on compounds identified by the screens generated through the collaboration; other financial terms were ND (9/00) |
| Aurora Biosciences Corp. (ABSC) | Pfizer Inc. (NYSE:PFE) | License/Merck receives nonexclusive license to Vivid screening technology for determining whether compounds interact with key metabolic enzymes, affecting their suitability as drugs | ND | Aurora will receive annual license fees, as well as payments for reagents, over several years (9/00) |
| Avant Immunotherapeutics Inc. (AVAN) | Pfizer Inc. (NYSE:PFE) | Development agreement for vaccines | $5.50 | Pfizer will develop animal health and food safety vaccines based on technology from Megan Health, which was acquired by Avant; Pfizer will pay $2.5M in an up-front license fee and make a $3M equity investment in Avant (12/00) |
| Avigen Inc. (AVGN) | BTG International Inc. (unit of BTG plc; LSE:BGC) | License agreement/gene therapy using Factor IX for treatment of hemophilia B | ND | Avigen licensed rights to Factor IX for use in its gene therapy delivery system; Avigen will pay an up-front fee and milestones (3/00) |
| Axon Instruments Inc. | AstraZeneca (UK; NYSE:AZN) | Development collaboration/development of an automated electrophysiology system for high-throughput drug screening | ND | AstraZeneca will supply a prototype instrument and key technology to Axon Instruments, which will develop it into a production-quality drug screening system for nonexclusive use by AstraZeneca, and for sale by Axon to other pharmaceutical companies (5/00) |
| Axys Advanced Technologies Inc. (unit of Axys Pharmaceuticals Inc.; AXPH) | Genomics Institute of the Novartis Research Foundation (unit of Novartis AG; Switzerland) | Research collaboration/use of small-molecule compounds created using Axys combinatorial chemistry technologies | ND | The institute will screen the compounds to detect changes in gene expression; in addition, the entities will develop novel chemistries together (1/00) |
| Axys Advanced Technologies Inc. | Bristol-Myers Squibb Co. (NYSE:BMY) | Research collaboration/use of Axys compounds for screening, plus transfer of technologies for reproducing and expanding the library | ND | Axys will receive payments for product delivery and technology transfer (2/00) |
| Battelle Pulmonary Therapeutics Inc. (unit of Battelle Memorial Institute) | Abbott Laboratories (NYSE:ABT) | License agreement/Battelle receives license to new products and drug delivery technology to develop therapies for a variety of respiratory diseases | ND | ND (6/00) |
| BCY LifeSciences Inc. (Canada; VSE:BCY) | AP Biotech (formerly Amersham Pharmacia Biotech; Sweden) | Supply agreement for DCF 987 | ND | AP Biotech will become the prime supplier for DCF 987, the active ingredient in BCY s lead product targeting cystic fibrosis and other lung disorders (10/00) |
| Biacore International AB (Sweden) | Pharmacia Corp. (NYSE:PHA) | Research collaboration/evaluation of Biacore's high-performance system in analyzing the serum protein binding of drug candidates | ND | Pharmacia will evaluate the system; further details ND (4/00) |
| BioFocus plc (UK) | Boehringer Ingelheim Pharmaceuticals Inc. (unit of Boehringer Ingelheim; Germany) | Research collaboration/compound design and synthesis, plus analysis of resulting biological screening data | ND | BioFocus will provide chemistry support and analysis of screening data (2/00) |
| Biogen Inc. (BGEN) | Elan Corp. plc (Ireland; NYSE:ELN) | Worldwide, exclusive collaboration to develop, manufacture and commercialize Antegren (natalizumab), which is in Phase II trials for multiple sclerosis | ND | The companies will work together to develop, manufacture and commercialize Antegren; they will share costs for ongoing development activities, as well as economic benefits; includes up-front and milestone payments (8/00) |
| Bioject Medical Technologies Inc. (BJCT) | Serono Laboratories Inc. (U.S. affiliate of the Ares-Serono Group; Switzerland) | License agreement/development of cus tomized version of Bioject s needle-free delivery system to deliver Serono s Saizan recombinant human growth hormone | ND | Serono has U.S. and Canadian rights to use the system for its growth hormone, and will pay an undisclosed license fee; the companies signed a supply agreement that commences upon FDA clearance (1/00) |
| BioNumerik Pharmaceuticals Inc. | Grelan Pharmaceutical Co. Ltd. (Japan) | Joint venture focused on oncologics | ND | Companies formed KI Pharmaceuticals LLC to focus on oncologics and enhance the Eastern presence of BioNumerik (11/00) |
| Bioreason Inc. | Pharmacia Corp. (NYSE:PHA) | Evaluation agreement/use of Bioreason s suite of process improve ments for screening | ND | Pharmacia will evaluate the impact of Bioreason s technology and services on lead discovery and characterization (2/00) |
| BioStratum Inc. | Shire Laboratories Inc. (unit of Shire Pharmaceuticals Group plc) | Development agreement for Pyridorin | ND | The companies will develop an extendedrelease formulation of Bio-Stratum s Pyridorin for kidney disease, which BioStratum will use in upcoming Phase III trials (11/00) |
| Biota Holdings Ltd. (Australia; ASX:BTA) | Glaxo Wellcome plc (UK: NYSE:GLX) | Research and development agreement/Glaxo received rights to develop and market worldwide a new influenza drug based on inhibition of neura minidase | ND | Biota will, subject to the final agreement, work with Glaxo to develop drug candidates with properties that will result in increased convenience in dosing regimen for both patient and doctor (9/00) |
| BioTransplant Inc. (BTRN) | Novartis Pharma AG (unit of Novartis AG; Switzerland; NYSE:NVS) | Creation of a new xenotransplantation research company | ND | The new company s research activities will be based in Boston; the share base of the company will be owned 67% by Novartis and 33% by BioTransplant; Novartis retains the rights to commercialization and research from the new company and BioTransplant will receive royalty payments (9/00) |
| Caliper Technologies Corp. (CALP) | SmithKline Beecham plc (UK; NYSE:SBH) | Joint development/new applications in synthetic chemistry using LabChip microfluidic technology | ND | Companies will focus on Caliper s platform to create chip-based chemistry applications for drug discovery (12/00) |
| Cambridge Antibody Technology plc (UK; LSE:CAT) | Wyeth-Ayerst Research (unit of American Home Products Corp.; NYSE:AHP) | License agreement/WyethAyerst gains an exclusive product license to develop antibody drugs specific for the b-amyloid peptide implicated in Alzheimer s disease | ND | Cambridge will receive an unspecified advance fee, clinical milestones and royalty payments from future sales if products reach the market; the deal is a follow-on to the companies 3/99 agreement (9/00) |
| Caprion Pharmaceuticals Inc. (Canada) | MicroMass UK Ltd. (UK; unit of Waters Corp.; NYSE:WAT) | Collaboration/support Caprion s proteomic research by applying Micromass mass spectrometry technologies | ND | Micromass will make a $7.5M investment in Caprion (11/00) |
| Celera Genomics Inc. (NYSE:CRA) | Takeda Chemical Industries Ltd. (Japan) | Database subscription/Five of Celera's genomics databases | ND | Five-year subscription that includes access to databases, bioinformatics systems and tools for viewing, browsing and analyzing genomic information (3/00) |
| Celera Genomics Inc. (NYSE:CRA) | American Home Products Corp. (NYSE:AHP) | Database subscription/subscription to all of Celera s current genomics databases | ND | Subscription includes access to the Celera Discovery System, which includes a comprehensive set of bioinformatics systems and tools for viewing, browsing and analyzing genomic information; AHP has option to obtain a nonexclusive license to certain other Celera intellectual property (7/00) |
| CeNeS Pharmaceuticals plc (UK; LSE:CEN) | Ares-Serono (Switzerland) | Research collaboration/use of CeNeS' drug delivery technologies to generate a novel formulation of a new fertility drug in development at Ares-Serono | ND | CeNeS will receive research fees and, if the product is successful, CeNeS will also manufacture the formulation at its GMP pharmaceutical plant in Scotland (3/00) |
| CeNeS Pharmaceuticals plc (UK; LSE:CEN) | Glaxo Wellcome plc (UK; NYSE:GLX) | Purchase agreement/highthroughput ion channel screening technology | ND | The companies will collaborate to enhance screening throughput of the system, called AutoPatch (12/00) |
| CeNeS Pharmaceuticals plc (UK; LSE:CEN) | Shire Pharmaceuticals Group plc (UK) | Research, development and license agreement/dopamine D1 agonist program to treat Parkinson s disease | 0.5 | Agreement includes milestone payments and royalties for CeNeS; Shire also made an equity investment of 150,000 in CeNeS (12/00) |
| Cetek Corp. | Schering-Plough Research Institute (unit of ScheringPlough Corp.; NYSE:SGP) | Research agreement/use Cetek's proprietary technology in screening new genomic targets | ND | Cetek will develop assays for SPRI's targets and screen against libraries from SPRI (6/00) |
| ChemBridge Corp. | AstraZeneca plc (UK) | Nonexclusive license/access to ChemBridge s PHARMA Core library | ND | AstraZeneca will use the library, intended to streamline the process of screeningbased drug discovery (10/00) |
| ChemBridge Corp. | Bristol-Myers Squibb Co. (NYSE:BMY) | Nonexclusive license/access to ChemBridge s PHARMA Core combinatorial lead discovery library | ND | Financial terms were ND (11/00) |
| ChemBridge Corp. | Kirin Brewery Co. Ltd. (Japan) | Access agreement/access to ChemBridge s PHARMA Core library | ND | Agreement gives Kirin nonexclusive access to PHARMA Core combinatorial lead discovery library; financial terms were ND (11/00) |
| ChemDiv Inc. | Bristol-Myers Squibb Co. (NYSE:BMY) | Database access/BristolMyers gains access to ChemDiv s experimentally confirmed, optimized combinatorial libraries of small-molecule compounds | ND | ChemDiv will be paid for delivery of several dozen compound libraries of its CombiLab set of diverse and focused libraries, also allowing for future payments should Bristol-Myers elect to acquire additional compounds, chemistry services or lead optimization; financial terms were ND (9/00) |
| Chiron Corp. (CHIR) | Glaxo Wellcome plc (UK; NYSE:GLX) | License agreement/smallmolecule therapeutics against hepatitis C virus | ND | Glaxo gains nonexclusive rights to research, develop and market small-molecule HCV therapies under Chiron s HCV patent portfolio (4/00) |
| Chrysalis Biotechnology Inc. | Abbott Laboratories (NYSE:ABT) | Option, license and development agreement/Chrysalin, a therapeutic for wound healing and tissue repair | ND | Agreement is for worldwide rights; further details were ND (4/00) |
| Coley Pharmaceutical Group (formerly CpG ImmunoPharmaceuticals) | SmithKline Beecham plc (UK; NYSE:SBH) | License agreement/development of immunotherapeutic products based on CpG DNA, including lead immune stimulant CpG 7909 | $72 | SmithKline gains a worldwide co-exclusive license to CpG DNA-based compounds for use in certain therapeutic and prophylactic vaccines for infectious diseases; in exchange, Coley could receive up to $72M in license fees, research funding and milestones, including an $8M up-front payment (1/00) |
| Corixa Corp. (CRXA) | Medicis Pharmaceutical Corp. (NYSE:MRX) | Multiyear development, commercialization and license agreement covering Corixa s psoriasis immunotherapeutic product, PVAC treatment | $107 | Provides Medicis with exclusive rights to PVAC treatment in the U.S. and Canada; Corixa will be responsible for development and manufacturing and Medicis will be responsible for commercialization and distribution; Medicis will pay Corixa an up-front payment of $17M with potential development milestone payments of $35M and commercialization and sales threshold milestone payments of $55M; Medicis also will purchase inventory from Corixa and pay a royalty on net sales (8/00) |
| Corixa Corp. (CRXA) | Purdue BioPharma L.P. (unit of Purdue Pharma) | Research and development agreement/Purdue will use its Synthebody technology to develop up to four therapeutic antibodies directed against cell-surface antibodies chosen from Corixa tumor-antigen discovery programs | ND | Purdue will provide Corixa with guaranteed research funding; based on the outcome of preclinical studies, Purdue may license the antibodies and targets from Corixa worldwide under currently defined terms that include up-front license fees, milestone payments and royalties (9/00) |
| Cortex Pharmaceuticals Inc. (OTC BB:CORX) | Shire Pharmaceuticals Group plc (SHPGY) | Option agreement/Shire will evaluate the use of Cortex's ampakine CX516 to treat attention deficit hyperactivity disorder | $1-plus | Shire will undertake a placebo-controlled, double-blind trial in ADHD patients; Cortex will receive $1M in an equity investment and cash; Shire has the right to convert option into exclusive worldwide license for ampakines for ADHD; if Shire exercises the option, it will fund all future developmental costs; Cortex would receive an up-front fee, milestones, research support and royalties on sales (4/00) |
| Cortex Pharmaceuticals Inc. (OTC BB:CORX) | Les Laboratoires Servier (Paris) | Three agreements for Cortex s ampakine technology | $11 | Servier will develop and commercialize Cortex s ampakine technology; the companies will research and develop new ampakines; they will enroll patients in North America and Europe for clinical trials of ampakine CX516 for improving memory; Cortex will receive an up-front payment of $5M and about $2M per year for a minimum of three years; Cortex also will receive potential milestones and royalties (10/00) |
| Corvas (CVAS) | Schering-Plough Corp. (NYSE:SGP) | Development agreement/development of synthetic antiviral compounds for prevention of hepatitis C virus infection | $2.50 | Corvas will receive $2.5M from ScheringPlough for the exclusive license of its technology and intellectual property related to drugs for the treatment of hepatitis C; Corvas may receive future royalties (5/00) |
| Crescendo Pharmaceuticals Corp. (CNDO) | Alza Corp. (NYSE:AZA) | Alza, which created Crescendo in 1997, exercised its option to license Viadur (Duros leuprolide, a once-yearly implant for palliative treatment of advanced prostate cancer) | ND | Alza will make payments based on worldwide sales and retains options to license each Crescendo product and an option to purchase all of the company s Class A common stock (3/00) |
| CuraGen Corp. (CRGN) | Ono Pharmaceutical Co. Ltd. (Japan) | Technology collaboration/use of CuraGen s platform of functional genomic technologies to gain a greater understanding of how genes influence and affect drug efficacy and toxicity | ND | Expandable, two-year collaboration in which Ono and CuraGen will collaborate in the application of molecular toxicology (6/00) |
| CV Therapeutics Inc. (CVTX) | Fujisawa Healthcare Inc. (Japan) | Development and marketing collaboration/development of CV-3146, a short-acting selective adenosine receptor agonist | $34 | FHI receives exclusive North American rights to CVT-3146 and backup compound; CVT will be responsible for managing the CVT-3146 clinical development program; FHI will be responsible for selling and marketing the product in North America; CVT will receive $10M from FHI and may receive up to an additional $24M in cash, based upon development and regulatory milestones; FHI will reimburse CVT for 75 percent of the development costs, and if approved by the FDA, CVT will receive royalties based on sales (7/00) |
| CyDex Inc. | Bristol-Myers Squibb Co. (NYSE:BMY) | License agreement/use of Cydex's captisol sulfobutyl ether b-cyclodextrin drug delivery technology to develop a second compound | ND | ND (5/00) |
| Cytokine PharmaSciences Inc. | Elan Corp. plc (Ireland; NYSE:ELN) | Formation of a joint venture company to develop the cytokine inhibitor, CNI-1493, using Elan s NanoCrys tal formulation technology | ND | The primary focus will be on Crohn s disease and other inflammatory conditions; both parties will contribute technology and other resources; Elan took an option to market CNI-1493 in noninfectious diseases upon completion of development (10/00) |
| CytRx Corp. (CYTR) | Merck & Co. Inc. (NYSE:MRK) | License agreement/TranzFect technology in DNA-based vaccines | ND | CytRx will receive an up-front payment and potential milestone and royalty payments (11/00) |
| CytRx Corp. (CYTR) | Undisclosed | Evaluation agreement/CytRx's gene delivery technology in a genebased vaccine for HIV | ND | Pharma company gains exclusive option to license the technology; CytRx will provide material and consulting services during option period in exchange for certain payments (3/00) |
| Deltagen Inc. | Merck & Co. (NYSE:MRK) | Research collaboration/production and analysis of knockout mice in order to characterize gene function | ND | Merck will provide target gene sequences, and Deltagen will produce and analyze knockout mice (2/00) |
| Deltagen Inc.(DGEN) | Schering-Plough Research Institute (unit of Schering Plough Corp.; NYSE:SGP) | Research collaboration/validation of small-molecule drug targets using knockout mice, which aid in characterizing gene function | ND | Schering-Plough will provide target gene sequences, and Deltagen will produce and analyze knockout mice (2/00) |
| Deltagen Inc.(DGEN) | Glaxo Wellcome plc (UK; NYSE: GLX) | Partnership involving Deltagen s DeltaBase gene function database and DeltaSelect drug target validation programs | $15 | Glaxo Wellcome is the first subscriber to Deltagen s database for mammalian gene function for new drug targets based on genomic databases; Glaxo will receive non- exclusive access to in vivo mammalian functional information or 250 new potential drug targets per year and will have access to Deltagen s patent portfolio for mammalian gene function; Glaxo will pay a subscription fee of $5M per year over a three-year term; Deltagen also may receive discovery and development milestones and access fees (9/00) |
| Deltagen Inc.(DGEN) | Pfizer Inc. (NYSE:PFE) | Collaboration/access to Deltagen s DeltaBase database | $25 | Pfizer will have nonexclusive access to DeltaBase s information on 750 genes for three years; Deltagen will receive $15M in license access fees, and another $10M if the agreement is extended for another two years (12/00) |
| De Novo Pharmaceuticals Ltd. (UK) | Aventis Pharmaceuticals (unit of Aventis SA; France; NYSE:AVE) | Technology access/De Novo will apply its platform of computer algorithms to provide novel, patentable small- molecule leads for Aventis under De Novo s Drug Design Partnership Program | ND | Aventis paid a technology access fee and will provide research funding for a period of 12 months; full details were kept confidential (9/00) |
| Diagnostic Products Corp. (NYSE:DP) | Minerva Pharmaceuticals Inc. | License agreement/development of immunoassays for a newly described, altered DNA synthesome malignancy protein found exclusively in patients with cancer of various types | ND | ND (9/00) |
| Discovery Therapeutics Inc. | Bayer AG (Germany) | License agreement/two Phase II anti-inflammatory drug candidates | ND | Discovery Therapeutics acquired two Phase II anti-inflammatory from drug candidates Bayer; agreement terms include license and milestone fees, plus royalties (7/00) |
| Diversa Corp. (DVSA) | Celanese Ltd. (unit of Celanese AG; NYSE:CZ) | Evaluation project/companies to discover and develop micro-organisms capable of producing chemical products at rates substantially higher than traditional microbial strains | ND | Celanese will fund discovery and optimization at Diversa and pay royalties on the sale of products utilizing improved strains; Celanese will have exclusive rights to commercialize strains discovered or developed within specified commodity and speciality chemical applications (8/00) |
| Diversa Corp. (DVSA) | Dow Chemical Co (NYSE:DOW) | Collaboration/develop and produce chiral compounds for active pharmaceutical ingredients, intermediates and other fine chemicals | ND | Diversa will use its high- throughput technologies to identify and develop enzymes, designed to exhibit enhanced performance to be used as biocatalysts in the develoment of pure chiral compounds; Diversa will receive undisclosed technology access fees, research and development payments, milestone payments and potential royalties (11/00) |
| Diversa Corp. (DVSA) | Glaxo Research and Development Ltd. (unit of Glaxo Wellcome plc; UK; NYSE:GLX) | Drug discovery research collaboration to identify drugs derived from the recombinant multigene PathwayLibraries | ND | Companies will jointly perform research to identify small molecules from Diversa s, and to screen these molecules; Glaxo will receive exclusive world-wide rights to designated biomolecules (12/00) |
| DoubleTwist Inc. | Berlex Laboratories Inc. (unit of Schering AG; Germany) | License agreement/DoubleTwist s clustering and alignment tools for genomic data | ND | Berlex gains a nonexclusive license (2/00) |
| DoubleTwist Inc. | Merck & Co. (NYSE:MRK) | Inc. License agreement/Prophecy | ND | Agreement grants Merck rights to the Prophecy annotated human genome database and associated software for data interpretation (11/00) |
| D-Pharm Ltd. (Israel) | Shire Pharmaceuticals Group plc (LSE:SHP) | License agreement/D-Pharma s DP-VPA, a chemical analogue of valproic acid for the treatment of central nervous system disorders | ND | D-Pharm receives an up-front fee and equity investment, as well as milestones; D-Pharm retains manufacturing rights and intends to become sole supplier of bulk compound, which Shire will purchase at a price that includes a royalty rate; Shire will be responsible for development and regulatory activities (3/00) |
| Dynavax Technologies Corp. | Aventis Pasteur (unit of Aventis SA; NYSE:AVE) | Research collaboration/development of new prophylactic and therapeutic vaccines for the treatment of infectious diseases using Dynavax s immunostimulatory DNA sequences | ND | Aventis Pasteur has the option to acquire exclusive worldwide rights to use ISS for specific disease targets in return for equity investments, research and development funding, milestones and royalties; Genavent, a venture capital fund of Societe Generale Asset Management and Aventis, will make an equity investment (2/00) |
| Ecopia BioSciences (Canada) | Merck & Co. Inc. (NYSE:MRK) | A 12-month agreement for research in undisclosed area | US$.125 | The agreement will cover a 12-month period an and will involve scheduled payments total ing US$125,000; both parties agreed not to disclose the other terms and the field of the agreement (10/00) |
| Electrofect | Boehringer Ingelheim GmbH International (Germany) | License agreement/Electrofect s electroporation technology for DNA delivery in the field of oncology | ND | Nonexclusive license; further details ND (2/00) |
| Elitra Pharmaceuticals Inc. | LG Chemical Ltd. | Research and development collaboration/the two companies will collaborate on the discovery and development of novel antimicrobial drugs for up to five years; Elitra and LG Chem will jointly share responsibilities for global development of all drug candidates | $30 | Elitra retains exclusive marketing rights in all territories outside of North America and Western Europe; both companies will pay reciprocal royalties on sales of products in their exclusive commercial territories; Elitra will receive $30M in the form of an up-front equity investment, research funding and milestone payments, assuming that the research continues for the full five-year term and only one compound from deal reaches the market (5/00) |
| Emisphere Technologies Inc. (EMIS) | DuPont Pharmaceuticals (unit of DuPont; NYSE:DD) | Development and marketing agreement/oral formulations of heparin and low-molecular-weight heparin utilizing Emisphere s proprietary drug delivery technology | ND | Emisphere will receive payments consisting of up-front fees, milestones and royalties (6/00) |
| Endorex Corp. (AMEX:DOR) and Elan Corp. plc (Ireland; NYSE: ELN) | Schein Pharmaceutical Inc. (NYSE:SHP) | License, co-development and supply agreement/iron chelating products using Elan s Medipad drug delivery system for treatment of certain genetic blood disorders resulting from iron overload | ND | Schein receives an exclusive worldwide sublicense to utilize Medipad for delivery of a Schein iron chelator; in the U.S. the groups will develop a drug/device product as part of a clinical testing program; Schein has U.S. marketing products and the companies will identify sublicensees for international markets (2/00) |
| Endorex Corp. (AMEX:DOR) | Novo Nordisk A/S (Denmark; NYSE:NVO) | Research and option agreement/formulation of Novo s Norditropin brand of human growth hormone using Endor ex s Orasome oral delivery system | ND | Novo has exclusive worldwide rights to license the Orasome system for Norditropin; companies will further evaluate product in animal models (3/00) |
| Entelos Inc. | Bristol-Myers Squibb Co. (NYSE:BMY) | Collaboration to evaluate various approaches to regulate human body mass and adipose tissue mass regulation approaches | ND | Entelos will use its PhysioLab technology to provide insight into different pathophysiologies leading to obesity and approaches to treat them (12/00) |
| Eos Biotechnology Inc. | Aventis Pasteur Ltd. (unit of Aventis SA; NYSE:AVE) | Research collaboration/harness new approaches to prevent the recurrence of cancer in patients treated with more traditional therapies; the two companies will identify novel genomics- derived targets for the development of cancer vaccines in two specific, undisclosed fields | ND | Aventis will obtain an exclusive license to develop vaccines against selected targets identified by Eos in return for up-front payment and research and development funding; Eos will receive milestone and royalty payments on products resulting from the collaboration that are eventually commercialized by Aventis (6/00) |
| EPIcyte Pharmaceutical Inc. | Dow Chemical Co. (NYSE:DOW) | Joint research and product development program/manufacturing large quantities of monoclonal antibodies in plants | ND | Companies plan to develop antibody-based products using EPIcyte s Plantibodies technology; Dow will receive exclusive licenses to Plantibodies products in the field of animal health (9/00) |
| EpiGenesis Pharmaceuticals Inc. (Italy) | Chisei Faramaceutici SpA | License and development agreement/EpiGenesis EPI-2010, an antisense oligonucle-otide for treatment of respiratory diseases | ND | EpiGenesis will receive development payments, as well as milestone fees and royalties on sales; Chisei will receive semi-exclusive marketing rights for the product and its use in asthma for Europe and other countries where Chisei has a presence; agreement includes possibility of future collaboration for additional indications (1/00) |
| EraGen Biosciences Inc. | Bayer Diagnostics (unit of Bayer AG; Germany) | License agreement/EraGen will license its AEGIS synthetic DNA base pair technology to Bayer for use in Bayer s branched DNA technology fornucleic acid testing, including its viral load test for HIV (HIV-1 RNA 3.0 assay) | ND | ND (9/00) |
| Evolutec Ltd. (UK) | Novartis Animal Health Inc. (Switzerland) | Joint research program/farm and companion animal vaccines | ND | Companies will determine if molecules discovered by Evolutec could be developed into farm and companion animal vaccines (11/00**) |
| EyeTech Pharmaceuticals Inc. | Iomed Inc. | Collaboration/develop a noninvasive drug delivery system for EyeTech s therapy targeting age-related macular degeneration of the eye | ND | EyeTech s therapeutic, EYE001, will be tested in Iomed s OcuPhor noninvasive transscleral delivery system for active drug transport to the retina and sub-retinal tissues (10/00) |
| FeRx Inc. | Elan Corp. plc (Ireland; NYSE:ELN) | Partnership/develop, manufacture and comrmecialize MTC-DOX to treat primary liver cancer | ND | Financial terms include equity and milestone payments to FeRx; the companies will share the costs of development, as well as commercialization revenues (11/00) |
| Genaissance Pharmaceuticals Inc. (GNSC) | Janssen Research Foundation (unit of Johnson & Johnson; NYSE:JNJ) | Multiyear, worldwide agreement/discovery, development and commercialization of HAP technology | ND | As part of the agreement, the R.W. Johnson Pharmaceutical Research Institute also will gain a license to the technology; terms were ND (11/00) |
| Gene Logic Inc. (GLGC) | Pfizer Inc. (NYSE:PFE) | Database subscription/access to Gene Logic s GeneExpress database of gene expression information for predictive toxicology applications | ND | Pfizer gains access to the database and will pay annual subscription fees (2/00) |
| Gene Logic Inc. (GLGC) | Boehringer Ingelheim International GmbH (Germany) | Subscription/for multiple segments of GeneExpress Suite of databases | ND | Boehringer will use the databases in its drug discovery and development programs (12/00) |
| Gene Logic Inc. (GLGC) | LG Chemical Ltd. (Korea) | Subscription/for a segment of the GeneExpress database | ND | LG Chemical will use the database in its drug discovery and development programs and has entered a partnership to develop therapeutic compounds for gastrointestinal disease (12/00) |
| Gene Logic Inc. (GLGC) | NV Organon (the Netherlands) | Subscription/for GeneExpress database and a research collaboration to develop a custom gene expression database | ND | Collaboration is focused on generating and evaluating gene expression information to aid in Organon s development of compounds for reproductive, psychiatric and cardiovascular diseases (12/00) |
| GeneFormatics Inc. | Schering-Plough Research Institute (unit of Schering-Plough Corp.; NYSE:SGP) | Research agreement/identification of novel therapeutic targets using GeneFormatics Fuzzy Functional Form technology | ND | GeneFormatics will apply its Fuzzy Functional Form technology to proprietary gene sequences of interest in an effort to elucidate the function of encoded proteins (6/00) |
| GeneFormatics Inc. | Bristol-Myers Squibb Co. (NYSE:BMY) | Research agreement/identification of novel therapeutic targets using GeneFormatics Fuzzy Functional Form technology | ND | GeneFormatics will apply its Fuzzy Functional Form technology to proprietary gene sequences of interest in an effort to elucidate function of encoded proteins; Bristol-Myers will use the technology in a first step toward a more comprehensive agreement (7/00) |
| Generex Biotechnology Corp. (GNBT) | Eli Lilly & Co. (NYSE:LLY) | Agreement to develop a buccal formulation of fine spray into the oral cavity using Generex technology | ND | Generex will receive certain initial fees and milestone payments, as well as royalty insulin administered as a payments; Lilly will receive exclusive, worldwide rights to products resulting and will be responsible for clinical trials, regulatory approvals and marketing worldwide (9/00) |
| Genetronics Biomedical Ltd. (Amex:GEB) | Undisclosed | Research collaboration/gene therapy using Genetronics' electroporation technology for gene delivery | ND | Agreement is the company's fifth in gene therapy field (4/00) |
| Genetronics Biomedical Ltd. (Amex:GEB) | Johnson & Johnson Research Pty Ltd. (Australia; unit of Johnson & Johnson; NYSE:JNJ) | Research collaboration/companies will explore the feasibility of using Genetronics electroporation platform technology to deliver nucleic acid materials into tumors in vivo | ND | Financial terms were ND (8/00) |
| Geneva Proteomics Inc. (Switzerland) | Schering-Plough Corp. (NYSE:SGP) | Contract sequencing/sequencing information | ND | Genome Therapeutics will generate high-quality DNA sequence information in support of gene discovery projects at Schering-Plough; Genome Therapeutics will employ its proprietary sequencing techniques, automation, bioinformatics and quality control procedures to generate sequence reads and provide analysis of the sequenced regions (6/00) |
| Geneva Proteomics Inc. (Switzerland) | Novartis Pharma AG (unit of Novartis AG; Switzerland; NYSE:NVS) | Alliance in proteomics to discover therapeutics, targets and biomarkers | $84 | Novartis will make a total equity investment of US$43M in Geneva Proteomics and will pay defined proteome fees of US$41M over four years; further license fees, milestone payments and reimbursements are possible; Novartis gains exclusivity for three years or longer for several hundred molecules and information on expression patterns studied in the alliance (10/00) |
| Genometrix Inc. | The Procter & Gamble Co. (NYSE:PG) | Technology access/Genometrix's GenoVista Partnership Program, which provides access to high-throughput microarray fabrication and hybridization services for genotyping and gene expression profiling | ND | P&G also gains access to the Internet-based VistaLogic Information System (4/00) |
| Genomica Corp. (GNOM) | Aventis Pharma (unit of Aventis SA; France; NYSE:AVE) | License agreement/Discovery Manager software | ND | Genomica licensed its Discovery Manager software to Aventis (11/00) |
| Genset SA (France; GENXY) | Sanofi-Synthelabo (France) | Pharmacogenomics collaboration/discovery and analysis of significant polymorphisms targets for drug development for undisclosed central nervous system disease | ND | Sanofi-Synthelabo receives an exclusive worldwide license to use the data and clones generated through the collaboration to develop and commercialize for the treatment of undisclosed diseases; Genset will receive research funding, milestones and royalties on resulting products (4/00) |
| Genset SA (France; GENXY) | Abbott Laboratories (NYSE:ABT) | Research collaboration/discovery of genes associated with bipolar disorder and Type II diabetes | ND | Abbott will receive a license to develop and commercialize therapeutic and diagnostic products based on genes identified through the collaboration; Genset will receive an up-front payment, research funding, milestones and royalties; Genset may exercise a put option to issue $10M worth of equity to Abbott (3/00) |
| Genzyme Molecular Oncology (GZMO) | Purdue Pharma LP | Discovery and license agreement related to the discovery and product development of up to 20 cancer antigens | $330 | Agreement has the potential to provide Genzyme Molecular Oncology with more than $330M in up-front and milestone payments if all 20 antigens are developed and approved for sale (10/00) |
| Gilead Sciences Inc. (GILD) | Glaxo Group Ltd. and Glaxo Wellcome Inc. (units of Glaxo Wellcome plc; UK; NYSE:GLX) | Exclusive, worldwide development and marketing agreement for GW1843U89 to treat cancer | ND | Gilead paid Glaxo an up-front license fee and will make milestone payments, as well as royalty payments; it also will cover research and development costs (12/00) |
| GLYCODesign Inc.(Canada) | Leo Pharmaceutical Products Ltd. (Denmark) | Development agreement/initial three-year joint venture to develop novel cardiovascular drug candidates | ND | Companies will equally share the costs of preclinical and initial clinical development up to the start of Phase II trials; Leo has an exclusive option to commercialize drug candidates in Europe (8/00) |
| GPC Biotech AG (Germany; Neuer Markt:GPC) | Bayer AG (Germany) | Research collaboration/GPC will perform compound mode-of-action studies using its Reverse Genomics technology program on up to 50 of Bayer s antibacterial development candidates | ND | GPC retains the rights for the expression Profile database generated from the collaboration for use in future Reverse Genomics collaborations with other companies and for use in its internal antibacterial R&D projects (8/00) |
| GPC Biotech AG (Germany; Neuer Markt:GPC) | Aventis Pharma Drug Innovation and Approval(Paris) | Research collaboration/ identify and validate interaction partners for an Aventis drug discovery target | ND | Aventis will use GPC s PathCode technology to identify and validate interaction partners for an Aventis drug discovery target (12/00) |
| Healthpoint Ltd. | Strakan Ltd. (a strategic partner of Access Pharmaceuticals Inc.; AMEX:AKC) | Option and license agreement/Healthpoint will gain rights to both Resi derm A and Residerm technology for the U.S., Canada, Mexico and the Caribbean | ND | Access shares in the licensing revenues generated from the ResiDerm technology and receives a royalty on worldwide sales; financial terms were ND (8/00) |
| Hemispherx Biopharma Inc. (AMEX:HEB) | Ie Sung International (Korea and Japan) | Agreement to accelerate development of Hemispherx s clinical programs in chronic viral diseases | ND | Agreement is for selected Pacific Rim countries (12/00) |
| Hemosol Inc. (Canada; TSE:HML) | Baxter Biotech S.a.r.l. (a unit of Baxter Healthcare Corp.; NYSE:BAX) | Agreement to purchase worldwide patents and intellectual property related to drug delivery technology | ND | Agreement will allow Hemosol to continue development of the technology; Hemosol will make cash payments on a progressive basis, along with a 4% royalty on commercial sales of resulting products (10/00) |
| HTS Biosystems Inc. | Mitsubishi Chemical Corp. (Japan) | Strategic relationship/Mitsubishi will gain premarket access to bioanalysis system that uses HTS Biosystems surface plasmon resonance array technology | ND | Mitsubishi will purchase systems for internal use and hold an option to purchase additional systems (12/00) |
| Human Genome Sciences Inc. (HGSI) | Aventis Behring LLC (unit of Aventis SA; France; NYSE:AVE) | Joint development and commercialization agreement/co-develop and jointly market an Aventis Behring plasma protein product | ND | Aventis and HGS will select the plasma protein and will use the strengths and capabilities of both organizations to capitalize on albumin fusion technology (10/00) |
| Human Genome Sciences Inc. (HGSI) | Dow Chemical Co. (NYSE:DOW) | Drug development/the treatment of B-cell malignancies | ND | Agreement combines Dow s bifunctional chelation agents with HGS s protein discovery, B Lymphocyte Stimulator protein; HGS seeks to develop a radiolabeled complex to treat B-cell malignancies, such as chronic lymphocytic leukemia, multiple myeloma and non-Hodgkin s lymphoma (10/00) |
| ICAgen Inc. | Yamanouchi Pharmaceutical Co. Ltd. (Japan) | Research and development collaboration/novel products aimed at several central nervous system disorders | ND | ICAgen will receive an up-front payment, research funding and milestones, plus royalties on products; ICAgen also has the right to develop and commercialize roducts for certain CNS indications and to commercialize products not pursued by Yamanouchi (3/00) |
| ICN Pharmaceuticals Inc. (NYSE:ICN) | Schering-Plough Corp. (NYSE:SGP) | Long-term strategic agreement/license drugs to treat hepatitis C and other conditions | ND | Schering-Plough has the right of first and last refusal to license two antiviral drugs, levovirin and viramidine, and other compounds that ICN may develop, as well as exclusive option for a worldwide license for up to three hepatitis C drugs to be developed |
| ICN Pharmaceuticals Inc. (NYSE:ICN) | Roche Holding AG (Switzerland) | Agreement to exchange Roche s ownership stake in ICN for an 8.7% ownership stake in ICN s Ribapharm | $120 | Roche has an option to increase its ownership stake in Ribapharm to 17.5% by exchanging additional ICN shares; Roche has about 3.9M shares of ICN (12/00) |
| Idec Pharmaceuticals Corp. (IDPH) | Taisho Pharmaceuticals Co. Ltd. (Japan) | Research and development agreement/develop of antibody therapeutics against macrophage migration inhibitory factor (MIF) for the treatment of inflammatory and autoimmune diseases | $35 | Agreement is valued at approximately $35M, including $18.5M in fixed R&D funding over the next four years; remaining value represents patent license fees and conditional milestones; Idec will share any such milestones with Cytokine PharmaSciences; Idec will retain exclusive commercialization rights in North, Central and South America, and Taisho will have exclusive commercialization rights in the rest of the world, paying Idec royalties on sales of therapeutic antibody products in its exclusive territories (6/00) |
| Idun Pharmaceuticals Inc. | Becton, Dickinson and Co. (NYSE:BDX) | License agreement/apoptosis reagents for use in the research market | ND | BD is exclusive licensee of Idun s apoptosis research reagents, and has the right to grant sublicenses; Idun receives an up-front payment, as well as royalties on sales (1/00) |
| IGI Inc. (AMEX:IG) | Fujisawa Pharmaceutical Co. Ltd. (Japan) | Development agreement/use of IGI s Novasome microencapsulation technology to develop a topical delivery system for a Fujisawa dermatological compound | ND | IGI will develop new formulation of undisclosed compound and will receive an upfront technology payment and potential milestones (1/00) |
| ILEX Oncology Inc. (ILXO) | BASF Pharma (Germany) | License agreement/ILEX receives an exclusive, worldwide license to BASF s anticancer compound, BSF 223651 | ND | The companies are finalizing an agreement giving ILEX an option for an exclusive worldwide license to Elinafide, another anticancer compound discovered by BASF; discussions are under way for additional BASF compounds (9/00) |
| ImClone Systems Inc. (IMCL) | SmithKline Beecham plc (UK; NYSE:SBH) | License agreement/proprietary antigens and related intellectual property owned by ImClone for inclusion in a vaccine against meningitis | ND | ImClone will receive an up-front fee and payments upon the achievement by SmithKline of certain clinical regulatory and milestones, plus royalties on sales (2/00) |
| ImmunoDesigned Molecules SA (France) | SanofiSynthelabo (France) | Research and development collaboration/covers IDM s usage of Sanofi-Synthelabo s protein interleukin-13 (IL-13); IL-13 will be used by IDM to prepare therapeutic vaccines designed to treat a number of cancer types | ND | IDM grants Sanofi-Synthelabo a right to an exclusive commercialization license of IDM IL-13-based cellular vaccines in Europe; each product will be subject to a specific licensing agreement; Sanofi-Synthelabo has taken a participation in IDM stock capital (5/00) |
| Incara Pharmaceuticals Corp. (INCR) | Elan Corp. plc (Ireland; NYSE:ELN) | Collaborative agreement/develop OP2000 | ND | The companies will pursue the clinical development of OP2000 while using Elan s Medipad drug delivery system (12/00) |
| Incyte Genomics Inc. (INCY) | American Home Products Corp. (NYSE:AHP) | Database agreement/access to Incyte's gene sequence databases for use in drug discovery and development | ND | Agreement includes access to Incyte s exclusive gene patent portfolio and ZooSeq and PathoSeq databases; Incyte could receive future milestone payments and royalties (7/00) |
| Incyte Genomics Inc. (INCY) | Bristol-Myers Squibb Co. (NYSE:BMY) | License agreement/Incyte s LifeExpress gene expression database | ND | Incyte could receive future milestone payments and royalties on sales of products that result (10/00) |
| Incyte Genomics Inc. (INCY) | Sumitomo Pharmaceuticals Co. Ltd. (Japan) | License agreement/Incyte s databases | ND | Sumitomo will license Incyte s LifeSeq Gold database, as well as the ZooSeq animal model database (12/00) |
| Inhale Therapeutic Systems Inc. (INHL) | Eli Lilly & Co. (NYSE:LLY) | Development program for inhaleable formulation of Forteo recombinant parathyroid hormone | ND | Companies plan to develop the pulmonary form of Forteo with Inhale s Inhance drug delivery platform (9/00) |
| Inpharmatica Ltd. (UK) | Parke-Davis (unit of WarnerLambert Co.; now part of Pfizer Inc.; NYSE:PFE) | Bioinformatics access/Inpharmatica s Biopendium platform for identifying, prioritizing and validating drug targets | ND | Parke-Davis signed a three-year, multimillion dollar agreement to become the first partner to gain access to Biopendium; Parke-Davis has an option to expand and extend the collaboration (1/00) |
| InSite Vision Inc. (AMEX:ISV) | SSP Co. Ltd. (Japan) | License agreement/two fluoroquinolone compounds, SS732 and SS734 | ND | InSite will develop SS734 into an ophthalmic dosage form, which will use the DuraSite technology; InSite will have exclusive rights, with the exception of Japan; the two companies will share the rights in Asia (12/00) |
| Insmed Pharmaceuticals Inc. (INSM) | Taisho PharmaPharmaceuticals Co. Ltd. (Japan) | Letter of intent for development and commercialization rights/INS-1, a low-molecular-weight oral drug for polycystic ovary syndrome and Type II diabetes | ND | Taisho signed a letter of intent for rights to Insmed s INS-1 in Japan and other Asian countries; Taisho will pay up-front, development, milestone and royalty payments pursuant to a definitive agreement to be negotiated; in addition, Taisho will invest several million dollars in Insmed equity (3/00) |
| Insmed Pharmaceuticals Inc. (INSM) | Taisho Pharmaceuticals Co. Ltd. (Japan) | Development agreement/development of Insmed's lead compound, INS-1, for the treatment of Type II diabetes and polycystic ovary syndrome | $32 | Taisho gains marketing rights for INS-1 in Japan and other Asian countries; Insmed will retain all rights to INS-1 in the rest of the world, including North America and Europe and will receive royalties on product sales in Japan and other Asian countries; Taisho will fund 20% of development costs in North America and Europe; the pre-commercialization value of the agreement is $32M, which includes license fees and pay ments for certain development and regulatory milestones (7/00) |
| Inspire Pharmaceuticals Inc. (ISPH) | Kirin Brewery Co. Ltd. (Japan) | License agreement/Kirin gains the right to develop and commercialize Inspire s lung disease diagnostic adjunct product, INS316 Diagnostic, in 21 Asian countries and regions, including Japan | ND | Inspire will receive an up-front payment in cash and milestone payments based on clinical success and approval; royalties on net sales will be paid to Inspire over the long term (9/00) |
| Isis Pharmaceuticals Inc. (ISIP) | Coley Pharmaceutical Group | Agreement to acquire Isis patents relating to immune stimulatory and modulatory phosphorothioate oligonucleotide technology | $10.70 | Isis will receive a one-time payment valued at $10.7M in return for the assignment to Coley of two issued U.S. patents and a pending U.S. patent application; the payment prepays all future royalties and milestones from a prior agreement (9/00) |
| Isis Pharmaceuticals Inc. (ISIP) | Pantheco A/S (Denmark) | License agreement/Pantheco licensed Isis third-generation antisense chemistry Peptide Nucleic Acid to treat diabetes and cardiovascular diseases | ND | Isis will receive a $1.1M licensing fee, payable in Pantheco shares, on approval and completion of Pantheco s financing, including royalties and milestone payments on products developed (9/00) |
| Isis Pharmaceuticals Inc. (ISIP) | Roche Molecular Systems Inc. (Switzerland) | License agreement of chemistry patents for use in production of RMS s diagnostic products | ND | Royalty-bearing license grants RMS nonexclusive worldwide access to Isis chemistry, in exchange for initial and ongoing payments (10/00) |
| Isis Pharmaceuticals Inc. (ISIP) | AstraZeneca plc (UK; NYSE:AZN) | Research collaboration/use of Isis antisensetechnology to assess and prioritize genes identified within AstraZeneca s genomics programs | ND | Isis will create antisense inhibitors to target genes in order to gather functional information (1/00) |
| Isis Pharmaceuticals Inc. (ISIP) | The R.W. Johnson Pharmaceutical Research Institute (unit of Johnson & Johnson; NYSE:JNJ) | Antisense target validation collaboration/Isis GeneTrove unit will use its antisense technology to assess and validate PRI gene targets | ND | This is the fourth GeneTrove target validation collaboration; financial details were ND (8/00) |
| InSite Vision Inc. (AMEX:ISV) | Pharmacia Corp. (NYSE:PHA) | Agreement/return rights for the ISV-900 technology | ND | InSite regained its rights for the technology for diagnostic and prognostic applications in glaucoma; InSite licensed the technology to Pharmacia in November 1999 (12/00) |
| Karo Bio USA (unit of Karo Bio AB; Sweden; SSE:KARO) | Aventis Pharma (unit of Aventis SA; France; NYSE:AVE) | Strategic alliance concerning Karo Bio s BioKey drug discovery technology | $32 | Karo Bio agreed to provide Aventis with access to the BioKey drug discovery technology for targets identified through Aventis genomics programs; Aventis has an option to extend the initial one-year term to three additional years; the value of the agreement can exceed $32M for Karo Bio, excluding royalties and assuming the development of two compounds (10/00) |
| Kos Pharmaceuticals Inc. (KOSP) | DuPont Pharmaceuticals Co. (NYSE:DD) | Development agreement/covers Nicostatin and exploration of additional opportunities in the cardiovascular and cho lesterol management areas | $80 | DuPont will provide funding of up to $80M, consisting of $17.5M in milestones and $32.5M for future clinical development; DuPont will also make an equity investment of up to $30M through FDA approval (companies will share promotion costs equally, and will share profits equally after deducting a royalty to Kos) (5/00) |
| Labopharm Inc. (Canada; TSE:DDS) | Aventis Pharmaceuticals Inc. (unit of Aventis SA; France; NYSE:AVE) | Feasibility and formulation agreement/use of Labopharm s controlled drug release technology Contramid, for development of two new formulations of an unnamed, top-selling Aventis product | ND | Labopharm will receive payments in addition to a success fee for the feasibility study, formulation of the drug and a pharmacokinetic study; financial terms were ND (8/00) |
| Lark Technologies Inc. (OTC BB: LDNA) | Novartis Research Foundation (unit of Novartis AG; NYSE:NVS) | Service agreement/Lark DNA sequencing services to support gene discovery efforts at Novartis | ND | Novartis will supply biological materials to Lark, which will provide high-throughput DNA sequencing for a fee; financial terms were ND (5/00) |
| Lexicon Genetics Inc. (LEXG) | Roche Bioscience (unit of Roche Holding Ltd.; Switzerland) | Sublicense agreement/use of certain aspects of Lexicon s positivenegative selection and isogenic DNA technol ogy to improve efficiency of genes targeted in knockout mice | ND | Roche will use the technology for its internal programs (1/00) |
| Lexicon Genetics Inc. (LEXG) | The R.W. Johnson Pharmaceutical Research Institute (unit of Johnson & Johnson; NYSE: JNJ) | Research collaboration/access to Lexicon s knockout mouse technology, and to its Seek Target Validation program to determine the function and pharmaceutical relevance of genes by analyzing knockout mice | ND | Multiyear agreement; details were ND (1/00) |
| Lexicon Genetics Inc. (LEXG) | G.D. Searle & Co. (unit of Monsanto Co.; now part of Pfizer Inc.; NYSE:PFE) | Research collaboration/access to Lexicon s knockout mouse technology | ND | Multiyear agreement under which Searle will pay annual access and project fees with minimum annual commitments (1/00) |
| Lexicon Genetics Inc. (LEXG) | Boehringer Ingelheim Pharmaceuticals Inc. (unit of Boehringer Ingelheim GmbH International; Germany) | Research collaboration/Internet access to Lexicon s gene sequence database and library of knockout mouse clones for use in determining the function of genes that represent potential gene targets | ND | Multiyear agreement under which BI will have nonexclusive access to Lexicon s OmniBank database in exchange for annual access fees; Lexicon also may receive royalties on sales of products developed using genes discovered using the database; BI also has access to knockout mice in exchange for agreed-upon fees with minimum annual commitments (2/00) |
| Lexicon Genetics Inc. (LEXG) | NV Organon (the Netherlands) | Research collaboration/access to Lexicon s knockout mouse technology | ND | Multiyear agreement under which Organon will pay annual access and project fees with minimum annual commitments (2/00) |
| Lexicon Genetics Inc. (LEXG) | American Home Products Corp. (NYSE:AHP) | Research collaboration/use of Lexicon's Omni Bank Internet Universal program determining gene functions that represent potential drug targets; includes access to a knockout mouse library and services, plus option to access Lexicon's Seek Target Validation program to determine gene function | ND | Multiyear agreement; AHP gains nonexclusive access to products and services in exchange for fees; Lexicon may receive royalties on sales of drugs and diagnostics developed using genes discovered in the OmniBank database; under a separate agreement, Lexicon granted a nonexclusive sublicense to AHP for use of certain aspects of positivenegative selection and isogenic DNA technology in AHP's in-house research programs (4/00) |
| Lexicon Genetics Inc. (LEXG) | Oriental Yeast Co. (Japan) | Collaboration agreement/web interface in the Japanese language allowing access to OmniBank | ND | Collaboration gives Lexicon entry into the Japanese drug discovery market (8/00) |
| Lexicon Genetics Inc. (LEXG) | Bristol-Myers Squibb Co. (NYSE:BMY) | Database access and license agreement/Bristol Myers gains access to the LexVision database containing phenotypic information from mouse gene knockouts and the OmniBank Library of mouse embryonic stem cell clones validation | $15-25 | Lexicon could receive between $15-25M in access and delivery fees, in addition to milestones and royalties on products BristolMyers develops using Lexicon s technology; the term of the agreement is five years, although either company may terminate after three years (9/00) |
| Lexicon Genetics Inc. (LEXG) | Bristol-Myers Squibb Co. (NYSE:BMY) | Nonexclusive sublicense for the use of certain aspects of Lexicon s positive-negative selection and isogenic DNA technologies | ND | BMS will use the technology for the generation of knockout mice for internal research purposes to gain predictive information about gene products (10/00) |
| Lexicon Genetics Inc. (LEXG) | Eli Lilly & Co. | Nonexclusive sublicense/use of certain aspects of Lexicon s positive-negative selection and isogenic DNA technologies | ND | Lilly will use the technologies in its internal discovery and target validation programs (11/00) |
| Life Technologies Inc. (OTC BB: LTEK) | Pfizer Inc. (NYSE:PFE) | Database subscription/database of information on the expression and localization of G protein-coupled receptors (GPRs) | ND | Pfizer receives early access to localization data on GPCR targets, which will be added continuously to the database over a two-year period (3/00) |
| Life Technologies Inc. (OTC BB: LTEK) | Novartis AG (Switzerland; NYSE:NVS) | Database subscription/a subscription to what LifeSpan says is the first database of information on the expression and localization of G proteincoupled receptors (GPCRs) | ND | Novartis will receive early access to localization data on GPCR targets, which will be added continuously to the database throughout a two-year period; Novartis will have the opportunity to prioritize the list of GPCR genes to be included in the database based on its internal interests (5/00) |
| Ligand Pharmaceuticals Inc. (LGND) | NV Organon (the Netherlands) | Research collaboration/discovery and development of small-molecule compounds for treating and preventing gynecological diseases mediated through the progesterone receptor | ND | Ligand received undisclosed up-front payments for research reimbursements and may receive milestones and royalties; Organon gains exclusive worldwide rights to manufacture and sell any resulting products (2/00) |
| Ligand Pharmaceuticals Inc. (LGND) | Bristol-Myers Squibb Co. (NYSE:BMY) | Research collaboration/will focus on the discovery design and development of orally active compounds that selectively modulate the mineralocorticoid receptor | ND | Ligand will receive an undisclosed payment and may receive up to $8.6M in research funding if research continues through 4/04, as well as additional undisclosed milestone payments and potential royalties; BMS will receive exclusive worldwide rights to all indications for compounds discovered in the field under this collaboration (5/00) |
| Lynx Therapeutics Inc. (LYNX) | Takara Shuzo Co. Ltd. (Japan) | License agreement/Lynx s Megaclone, Megasort and Massively Parallel Signature Sequencing Technologies | ND | License provides Takara with the rights to the technologies exclusively for at least five years, and nonexclusively thereafter; Takara also gained a nonexclusive right to manufacture and sell microarrays containing content identified by the Lynx technologies; Takara will make equity purchases in Lynx and will pay technology access fees and royalties; Lynx also will receive payments for the sale of reagents used in applying Lynx s technologies (11/00) |
| Lyotropic Therapeutics Inc. | Elan Pharmaceutical Technologies (unit of Elan Corp. plc; Ireland; NYSE:ELN) | Joint venture/research, development and commercialization of pharmaceutical products | ND | The companies will develop the products using Lyotropic s LyoCell and Elan s NanoCrystal drug delivery technologies; the joint venture will be a subsidiary of Lyotropic (11/00) |
| Martek Biosciences Corp. (MATK) | Abbott Laboratories (NYSE:ABT) | License agreement/use of long-chain polyunsaturated fatty acids in infant formulas | ND | Abbott receives a nonexclusive license to the technology in exchange for initial cash payments and royalties on resulting products (4/00) |
| Maxim Pharmaceuticals Inc. (MAXM) | F. Hoffmann La Roche AG (Switzerland) | Development collaboration/development of Maxim s lead drug, Maxamine (histamine dihydrochloride), in combination with Roche s investigational pegylated interferon a-agent, Pegasys compound, to advance the treatment of cancer and hepatitis C | ND | Both companies will undertake clinical trials and other activities designed to seek regulatory approval of the combination of Maxamine and Pegasys for the treatment of hepatitis C and certain cancers; Roche will perform the monitoring and data management of the trials at its own cost, and the companies will share equally the thirdparty costs of the trials; each company will retain marketing responsibilities and revenues for its respective drug, although they will cooperate in the training of their respective sales forces (8/00) |
| Maxygen ApS (unit of Maxygen Inc.; MAXY) | H. Lundbeck A/S (Denmark) | Research, development and licenset/Lundbeck has licensed rights to an unnamed protein pharmaceutical product that could be used for central nervous system diseases | ND | Maxygen has retained rights for neurological indications in key Asian markets and global rights for those outside of central nervous system diseases, including inflammatory disease and cancer; Maxygen will receive license fees and research and development funding, including milestone payments and royalties on product sales (9/00) |
| Medarex Inc. (MEDX) | Kirin Brewery Co. Ltd. (Japan) | Cross-licensing agreement and research collaboration/mouse technology for creating monoclonal antibodies (Medarex s HuMAb Mouse and Kirin s Transchromosomic Mouse) | $12M | Kirin will pay a $12M up-front fee for exclusive rights to distribute the technology in Asia; Medarex gains exclusive distrbution rights to Kirin s mouse technology outside of Asia; companies will exchange broad licenses, subject to milestones and royalties, for in-house use of each other s technology for development of antibody therapeutics; companies will initiate a research collaboration to create a novel approach for development of fully human antibodies by combining their technologies; alliance could generate third-party milestones of more than $250M (1/00) |
| Medarex Inc. (MEDX) | Eli Lilly & Co. | Agreement to produce fully human antibodies for a number of Lilly disease targets | ND | Medarex will receive an immunization fee for each target against which it raises an antibody; Medarex also will receive license fees, as well as payments for milestones and potential royalties (11/00) |
| MediGene AG (Germany; Neuer Markt:MDG) | Aventis Pharma AG (unit of Aventis SA; France; NYSE:AVE) | Research collaboration/Medigene s gene therapy tumor vaccine using recombinant adenoassociated viruses for treatment of malignant melanoma | $34M | Aventis gains an exclusive license to develop and commercialize the vaccine in 37 countries (including the European Union, North America and Japan) with rights to grant sublicenses; total deal value could amount to $34M, including up-front frees, milestones and R&D funding; in addition, MediGene will receive royalties on sales and promotion rights for most Eastern European countries and a number of South American, Far East and Middle East countries; Aventis will be responsible for manufacturing GMP material and will handle Phase III trials and regulatory matters (2/00) |
| MediGene AG (Germany; Neuer Markt:MDG) | Schering AG (Germany) | Development agreement/MediGene's viral vaccine to treat precancerous lesions of the cervix caused by human papilloma viruses | US$25 | Schering received a worldwide exclusive license, with MediGene retaining an option for distribution in countries in which Schering decides not to commercialize; Schering will pay up to $25M in up-front and milestone payments and research funding, plus royalties on any resulting products (3/00) |
| MedImmune Inc. (MEDI) | SmithKline Beecham Biologicals (unit of SmithKline Beecham plc; UK; NYSE:SBH) | License agreement/MedImmune s Streptococcus pneumoniae vaccine technology | $30 | SmithKline will pay up-front payment and future milestones totaling more than $30M, plus royalties on product sales (7/00) |
| Medinox Inc. | Fuso Pharmaceutical Industries Ltd. (Japan) | Development and marketing agreement/NOX100, Medinox's nitric oxide-neutralizing compound for sepsis | ND | Fuso gains exclusive rights to develop and market NOX-100 for sepsis and one additional indication in Japan; Fuso made an equity investment and paid an up-front fee, and may pay milestones and royalties; Medinox retains manufacturing rights (5/00) |
| MethylGene Inc. | MGI Pharmaceuticals Inc. (MOGN) | License, research and development agreement/for MG98, a secondgeneration mRNA inhibitor, and novel small-molecule DNA methyl transferase inhibitors for anticancer activity | $16 | MethylGene will receive an initial cash payment, followed by milestone payments based on progress of receiving North American approvals; MGI Pharma will fund the ongoing development of MG98 and the DNA methyltransferase small-molecule inhibitors and make a $6.8M equity investment in MethylGene; MethylGene will also receive royalties on net sales revenue and retain a co-promotion right in North America and all rights outside of North America (8/00) |
| Microcide Pharmaceuticals Inc. (MCDE) | Daiichi Pharmaceutical Co. Ltd. (Japan) | Research collaboration/discovery and development of inhibitors that will overcome the effect of efflux pumps in Pseudomonas aeruginosa | ND | Microcide retains co-promotion rights for North America and will receive milestones and royalties on any resulting products; those products are expected to be used in combination with Daiichi's quinolone antibiotics to increase their effectiveness against Gram-negative bacteria (5/00) |
| Microcide Pharmaceuticals Inc. (MCDE) | Schering-Plough Animal Health | Research collaboration and license agreement to discover and develop improved veterinary antimicrobial drugs | ND | Schering-Plough will have worldwide rights to products resulting; Microcide will receive an up-front payment and research support payments over two years, and milestone and royalty payments on resulting products (11/00) |
| Millennium Pharmaceuticals Inc. (MLNM) | Taisho Pharmaceutical Co. Ltd. (Japan) | License agreement/Millennium s LDP-977 for the treatment of chronic asthma | ND | Companies signed a letter of intent granting Taisho an exclusive license in Japan, Asia and Europe; Taisho funds all research and development expenses in Japan and Asia, and two-thirds of the expenses in the U.S. and Europe; Taisho also will pay a licensing fee, plus milestones based on progress in its territories; Millennium will manufacture the product for Taisho and receive supply fees based on sales; Taisho has the right of first negotiation for commercialization in the U.S. should Millennium seek to sublicense in that territory (1/00) |
| Millennium Pharmaceuticals Inc. (MLNM) | Aventis Pharma (unit of Aventis SA; France; NYSE:AVE) | Research collaboration and technology transfer/joint effort to discover targets and develop and commercialize drugs for inflammatory diseases; joint development of drug discovery technologies; transfer of key elements of Millennium's technology platform to Aventis | $450 | Alliance includes four separate arrangements covering inflammation, technology development and transfer, and an equity investment; under technology transfer, Aventis gains rights to Millenium's drug discovery technologies in exchange for payments up to $200M over a five-year period; under equity investment agreement, Aventis will invest $250M in Millennium common stock ($150M at closing and two $50M purchases in 2001); the inflammation and technology development agreements call for joint funding (6/00) |
| Millennium Pharmaceuticals Inc. (MLNM) | Biacore AB (Sweden; BCOR) | Research collaboration/co-development of a new generation of surface plasmon resonance array chip technology for use in high-throughput biological evaluations for drug discovery | ND | Each company will commit a dedicated research team to the joint program; Biacore will supply and develop all necessary SPR technology expertise, array chips, consumables and software; Millennium will contribute specific assay and drug discovery applications expertise; Biacore will have rights to market instrument-related developments; Millennium will benefit from early access to the technology and effect on productivity in the company's drug discovery programs (6/00) |
| Millennium Predictive Medicine (MPMx; unit of Millennium Pharmaceuticals Inc.; MLNM) | Becton Dickinson and Co. (NYSE:BDX) | License agreement/colon cancer diagnostics | ND | Becton paid Millennium a licensing fee in exchange for certain research and development rights to select diagnostic markers and related intellectual property developed by Millennium; Becton has option to exercise a commercial license in the future (7/00) |
| Modex Therapeutics Ltd. (Switzerland; SWX:MDXN) | Novartis AG (Switzerland; NYSE:NVS) | Research and development collaboration/evaluate Modex s Encapsulated Cell Therapy (ECT) system s potential to treat solid tumors through the continuous delivery of an undisclosed protein | ND | Novartis will fund all research and evaluation up to 18 months; Novartis will then have the option to license the ECT technology for this clinical indication and other protein-responsive diseases (6/00) |
| Myogen Inc. | Knoll AG (unit of BASF Pharma) | Co-development agreement for BSF 208075 | ND | Myogen agreed to pay BASF an up-front fee and will complete Phase II testing in exchange for a share in the potential commercial value; both companies have an option to carry out Phase III trials under certain circumstances (12/00) |
| Myriad Genetics Inc. (MYGN) | F. Hoffmann La Roche Ltd. (Switzerland) | Research collaboration/use of Myriad s ProNet to discover drug targets for treating heart disease | $13 | Myriad will receive up to $13M in research funding, license fees and milestones, plus royalties on any sales (1/00) |
| Myriad Genetics Inc. (MYGN) | Hitachi Ltd. (Japan; NYSE:HIT) | License agreement/Myriad's ProNet proteomic screening technology; Hitachi will establish a ProNet facility to expedite discovery of proteinprotein interactions for Japanese customers | $26 | Myriad will receive an up-front license fee of $15M and research funding of $11M over three years (5/00) |
| NeoGenesis Inc. | Merck & Co. Inc. (NYSE:MRK) | Collaborative research agreement | ND | NeoGenesis will uses its Chemical Genomics technology platform to identify and optimize chemical compounds for new drug discovery leads against multiple targets (12/00) |
| Neurocrine Biosciences Inc. (NBIX) | Taisho Pharmaceutical Co. Ltd. (Japan) | License option/Neurocrine s altered peptide ligand (NBI6024) for diabetes | $45 | Taisho gains an exclusive option to license rights for Europe and Asia; approximate value of the collaboration is $45M, which includes licensing and option fees, milestones and reimbursement of 50% of worldwide development expenses; in addition, Neurocrine will receive royalties on sales in Taisho s territories (1/00) |
| Neurome Inc. | Elan Corp. plc (Ireland; NYSE:ELN) | Research partnership for three years | $4 | The partnership may generate up to $4M in service revenue for Neurome, along with shared ownership of the diagnostic and therapeutic applications of the genes, circuits and mechanisms identified in the research; the parties will analzye a mouse model of Alzheimer s disease to identify and exploit molecules and pathways relevant to diagnosis and treatment (10/00) |
| NeuroSearch A/S (Denmark; Copenhagen: NEUS) | Abbott Laboratories (NYSE:ABT) | Research collaboration/use of NeuroSearch s drug discovery platform for a family of ion channels to discover compounds for treatment of a variety of central and peripheral nervous system disorders | $17 | Abbott gains exclusive worldwide rights to compounds discovered in the collaboration; Abbott will finance all R&D done by both project partners, and will pay up to $17M in milestones for each successfully developed compound, as well as royalties on sales (1/00) |
| NeuroSearch A/S (Denmark; Copenhagen: NEUS) | Glaxo Wellcome plc (UK; NYSE: GLX) | Development agreement/NeuroSearch s antidepressant, NS2389 | $57 | NeuroSearch will receive a first-phase payment of $10M, additional premarketing milestones of up to $47M and royalties on any sales (1/00) |
| NeuroSearch A/S (Denmark; Copenhagen: NEUS) | NV Organon (the Netherlands) | Discover, develop and commercialization/novel agonists of gamma amino butyric acid (GABA) | $12.80 | NeuroSearch will receive up to EUR15M (US$12.8M) in up-front and milestone payments, as well as potential royalties; Organon is funding all of the research and development costs and will gain exclusive worldwide rights to whatever compounds emerge from the program (11/00) |
| Nortran Pharmaceuticals Inc. (Canada) | AstraZeneca plc (UK; LSE:AZN) | Exclusive worldwide license agreement/the development and marketing of Nortran s antiarrhythmic drug | ND | AstraZeneca will make an up-front payment, in addition to milestone and royalty payments and all development and marketing costs for the single small-molecule candidate (10/00) |
| Novavax Inc. (AMEX:NOX) | King Pharmaceuticals Inc. (NYSE:KG) | Agreement for exclusive worldwide rights to develop, manufacture and market HPV-16 VLP vaccines | $25 | King gains exclusive worldwide rights and agreed to make a $25M convertible debenture investment in Novavax; Novavax will also receive a 17% royalty on net sales (12/00) |
| NPS Pharmaceuticals Inc. (NPSP) | Abbott Laboratories (NYSE:ABT) | License agreement/NPS-1776, a compound with potential neuroscience applications, plus other compounds | ND | Abbott gains exclusive worldwide development and marketing rights and will provide research funding and milestone payments, plus royalties on resulting products (3/00) |
| Oasis Bioscience Inc. | Sugen (unit of Pharmacia Corp; NYSE:PHA) | Research agreement/validate oncology targets for drug discovery | ND | Oasis will develop knockout reagents to investigate and clarify the role of genes (12/00) |
| Oceanix Biosciences Corp. | Glaxo Wellcome plc (UK; NYSE: GLX) | Research collaboration and database access/Oceanix s Receptor Selectivity Mapping Database, which contains data on interactions between compounds and disease-related targets | ND | Glaxo gains nonexclusive access to database for internal use in drug discovery and development; Glaxo will provide slected compounds to Oceanix to be screened against a range of molecular targets and included in the database and shared between Oceanix and Glaxo; agreement could encompass joint development of data mining tools; Glaxo will pay access and screening fees (2/00) |
| Odyssey Pharmaceuticals Inc. | Becton, Dickinson and Co. (NYSE: BDX) | License agreement/rights to certain substrates for cell-based gene function and highthroughput screening applications | ND | Odyssey has the worldwide right to make, use and sell the compounds, fluorescent and chromogenic substrates for beta-lactamase, for cell-based drug discovery and gene function assays (12/00) |
| OncoImmunin Inc. | Wyeth-Ayerst Laboratories (unit of American Home Products Corp.) | Research collaboration and license option/image-based caspase high-throughput screening system | ND | Wyeth-Ayerst will pay milestone payments and royalties on product sales if it picks up the option to license the drug delivery technology (12/00) |
| Oncolytics Biotech Inc. (Canada; TSE:ONC) | Pfizer Inc. (NYSE:PFE) | Worldwide licensing agreement for reovirus | ND | Agreement is for the development and marketing of reovirus for animal use (11/00) |
| Onyx Pharmaceuticals Inc. (ONXX) | EPTICO Ltd. (UK) | Multiyear research collaboration to identify, evaluate and select novel prodrugs that are converted by the enzyme nitroreductase | ND | Agreement is aimed at expanding Onyx s selectively replicating anticancer Armed Therapeutic Virus platform; Onyx also is gaining access to the gene encoding the enzyme nitroreductase (8/00) |
| Orchid BioSciences Inc. (ORCH) | Eli Lilly & Co. (NYSE:LLY) | Commercial single nucleotide polymorphism (SNP) genotyping service agreement | ND | Orchid will perform high-throughput SNP scoring on samples provided by Lilly; further details were ND (10/00) |
| OSI Pharmaceuticals Inc. (OSIP) | American Home Products Corp. (NYSE:AHP) | Cross-licensing agreement/OSI s gene transcription patent estate and a family of patents covering yeast screening technologies developed by AHP unit American Cyanamid | ND | OSI gains access to American Cyanamid technology, including claims for recombinant expression of a variety of targets in yeast, including G protein-coupled receptors; cross-license allows American Cyanamid to retain exclusive rights to use the GPCR technologies in the agricultural field (1/00) |
| OSI Pharmaceuticals Inc. (OSIP) | The R.W. Johnson Pharmaceutical Research Institute (unit of Johnson & Johnson; NYSE:JNJ) | License agreement/OSI s gene transcription patent estate | ND | OSI will receive annual fees, together with milestones and success payments from small-molecule gene transcription modulators developed and marketed; license is nonexclusive (1/00) |
| Oxford BioMedical plc (LSE:OXB) | AstraZeneca plc (UK; NYSE:AZN) | Research collaboration/use of Oxford s LentiVector gene delivery technology to deliver genes that are central to a number of disease processes, including asthma | ND | ND (2/00) |
| Oxford GlycoSciences plc (UK; LSE:OGS; OGSI) | Bayer AG (Germany) | Research collaboration/use of OGS s proteomics technology to identify disease-associated proteins as potential targets for drug discovery | ND | Bayer has committed funding for an initial term of two years and will pay milestones and royalties; parties will jointly own any intellectual property arising from collaboration, and OGS will have exclusive rights to commercialize diagnostic markers identified (3/00) |
| Oxford GlycoSciences plc (UK; LSE:OGS; OGSI) | Glaxo Wellcome plc (UK; NYSE: GLX) | Multidisease biomarker collaboration | ND | Collaboration will use high-throughput proteomics technology; Glaxo Wellcome will fund research and may obtain an exclusive right to negotiate for the acquisition of OGS s diagnostic rights (12/00) |
| Oxford GlycoSciences plc (UK; LSE:OGS; OGSI) | Pfizer Inc. (NYSE:PFE)) | Research agreement to discover new biomarkers and drug development targets in Alzheimer s disease and atherosclerosis | ND | OGS will apply its proteomics technology in the collaboration, which is a continuation of the April 1998 joint research collaboration; Pfizer will provide research funding and will make milestone payments; OGS will grant Pfizer a nonexclusive license to use its databases; Pfizer also will make another equity investment in OGS (12/00) |
| Pharmacopeia Inc. (PCOP) | NV Organon (the Netherlands) | Research collaboration/small-molecule antagonists of interleukin-8 for treating inflammatory diseases | ND | Pharmacopeia will receive research funding to pursue further chemical optimization of lead compounds already identified by Pharmacopeia; Organon will handle development and commercialization of lead compound (1/00) |
| Pharmacopeia Inc. (PCOP) | Elan Corp. plc (Ireland; NYSE:ELN) | Research collaboration/discovery of small-molecule inhibitors of bsecretase for treatment of Alzheimer s disease | ND | The companies will pool their scientific and intellectual property and share all associated costs and revenues associated with research, development and marketing of potential inhibitors of b-secretase; financial terms were ND (8/00) |
| Pharmacopeia Inc. (PCOP) | Schering AG (Germany) | Research collaboration to focus on the chemical optimization of lead compounds | ND | Pharmacopeia achieved a milestone in an existing agreement between the companies concerning the identification of lead compounds; those compounds are the focus of this new collaboration (9/00) |
| Pharming Group NV (the Netherlands) | Baxter Healthcare Corp. (NYSE:BAX) | Research and development collaboration/recombinant human C1 inhibitor to treat hereditary angioedema | ND | Baxter gains worldwide marketing rights for the hereditary angioedema indication; development costs will be shared, and Pharming will receive license fees; upon commercialization, a royalty arrangement will be implemented (3/00) |
| Phase-1 Molecular Toxicology Inc. | PE Biosystems Group (NYSE:PEB) | Development collaboration/high-throughput gene expression assays for preclinical drug toxicity evaluations | ND | Phase-1 and PE will share technical responsibility for the development and validation of a panel of approximately 50 gene expression assays; Phase-1 will choose the target genes and validate the assays for the targets; PE will design, develop, manufacture and market the assays; Phase-1 also will develop positive controls (full-length cDNA clones) to test specificity of the assays; PE will market those controls; during the final stage of the project, Phase-1 will create a database of the gene expression profiles for targeted genes for cDNA samples from rat and human cells exposed to 50 reference compounds; reagents for this panel will be made available in an ABI PRISM card format (3/00) |
| Phase-1 Molecular Toxicology Inc. | Schering AG and Berlex Biosciences (Germany) | Collaboration for novel methods for toxicological screening of preclinical candidates | ND | Phase-1 will take its human molecular in vitro, and rat in vitro and in vivo, data to create a predictive model of response and put the power in the hands of its partners (8/00) |
| PPD GenuPro (unit of PPD Inc.; PPDI) | Alza Corp. (NYSE:AZA) | Exclusive license to dapoxetine for genitourinary therapies, including premature ejaculation | ND | Alza will receive worldwide rights to develop and commercialize dapoxetine and be responsible for manufacturing, clinical, regulatory, sales and marketing costs resulting from the license; GenuPro will receive an undisclosed up-front payment, as well as royalties and milestone payments (12/00) |
| PPL Therapeutics plc (UK;LSE:PTH) | Bayer Biological Products (unit of Bayer AG; Germany) | License and development agreement/worldwide license to develop transgenically produced recombinant replacement therapies in aerosol form for a-1antitrypsin deficiencyrelated emphysema and for cystic fibrosis, initially to conduct a placebocontrolled Phase III efficacy study for ATT deficiency, then manufacture and commercialize the aerosol formulation globally for AAT, and later for cystic fibrosis | $40 | Bayer will bear the costs of clinical development and marketing; PPL will be responsible for exclusive product manufacturing; Bayer will make an upfront investment of $15M in purchase of PPL equity at 2.15 a share; PPL will also receive up to $25M in milestone payments if progress is made in registering indications and in driving sales growth; of this, a total of $15M will be paid up to and at the time of approval of the product for AAT deficiency-related emphysema; PPL will receive production revenues and royalties on product sales (8/00) |
| Progen Industries Ltd. (Australia; PGLAF) | Medigen Biotechnology Corp. | Research and development agreement/development of Progen s PI-88 for the potential treatment of cancer and cardiovascular disease | A$11 (US$6.3) | Under a subscription agreement, Medigen will purchase an equity stake in Progen for $11M; the equity comprises approximately 2.75M shares at A$4 (US$2.41) and 1M options; Progen will receive a 19.9% equity stake in Medigen and certain anti-dilution rights; Medigen will be entitled to receive 15% of Progen s future PI-88 revenues generated from cancer and cardiovascular diseases subject to a successful joint venture alliance (6/00) |
| Protein Design Labs Inc. (PDLI) | Fujisawa Pharmaceutical Co. Ltd. (Japan) | Research collaboration/use of PDL s humanization technology for an antibody to treat inflammatory and immunologically mediated diseases | $1.50 | Fujisawa will pay a $1.5M signing fee, plus milestones, annual maintenance fees and royalties on any product sales sales (2/00) |
| Protein Design Labs Inc. (PDLI) | American Home Products Corp. (NYSE:AHP) | License agreement/AHP has exercised its option to obtain a nonexclusive license under PDL s antibody humanization patents to market Mylotarg (gemtuzumab ozogamicin for injection) in Japan and other Asian countries | ND | PDL will receive an additional nonrefundable, noncreditable signing and licensing fee from AHP and will be entitled to annual maintenance fees and royalties on any Mylotarg sales (5/00) |
| Protein Design Labs Inc. (PDLI) | Chugai Pharmaceutical Co. Ltd. (Japan) | License agreement/Protein Design Labs antibody humanization patents | $6.04 | Chugai will receive nonexclusive, worldwide licenses under PDL's antibody humanization patents for an undisclosed number of Chugai antibody targets; Chugai will pay PDL nonrefundable, noncreditable upfront signing and licensing fees totaling $6.04M, annual maintenance fees and royalties on any product sales (5/00) |
| Protein Design Labs Inc. (PDLI) | Toagosei Co. Ltd. (Japan) | Development agreement/antibody against vascular endothelial growth factor developed by Toagosei and humanized by PDL; PDL and Toagosei will develop the antibody for potential uses in the treatment of cancer | ND | PDL has exclusive development and marketing rights to anti-VEGF antibody in North America and the first option to obtain exclusive rights to market the antibody in Europe and other markets, except Japan, where Toagosei has exclusive rights to market SMART anti-VEGF; PDL will direct the clinical development program, and the companies will share development costs and profits from sales of the antibody in markets outside Japan (5/00) |
| Protein Design Labs Inc. (PDLI) | Eli Lilly & Co. (NYSE:LLY) | Two agreements to adapt for human use murine antibodies from Lilly | $3.06 | PDL will receive an up-front signing fee of $1.7M, milestone payments, annual maintenance fees and royalties on sales in the first agreement; it will receive an up-front signing fee of $1.36M, milestone payments, annual maintenance fees and royalties on sales in the second agreement (9/00) |
| Proteome Systems Ltd. (Australia) | Shimadzu Corp. (Japan) | Development collaboration/instruments for the near-parallel highthroughput screening of proteins | ND | Collaboration will combine Proteome's chemical printing technology with Shimadzu s MALDI mass spectrometry (3/00) |
| Quantum Dot Corp. | Genomics Institute of the Novartis Research Foundation (unit of Novartis AG; Switzerland) | Research collaboration/use of Quantum Dot s nanocrystals to develop biological assays for proteome analysis and gene expression | ND | ND (3/00) |
| Quark Biotech Inc. | Shionogi & Co. (Japan) | License agreement and research collaboration/use of Quark s technology to discover and analyze genes associated with osteoarthritis | ND | Quark will identify and characterize genes; Shionogi will develop and manufacture pharmaceutical and diagnostic candidates resulting from the genes and will have exclusive marketing rights in the Far East; companies will share marketing rights elsewhere (1/00) |
| ReNeuron (UK) | Novo Nordisk A/S (Denmark) | License agreement/Novo Nordisk out-licensed the development project NNC 05-1869 (ReN1869) and a group of related compounds to ReNeuron | ND | Under the terms of the agreement, ReNeuron is responsible for the Phase II clinical development program (5/00) |
| Rigel Pharmaceuticals Inc. (RIGL) | Novartis Pharma AG (Switzerland; NYSE:NVS) | Discovery collaboration/companies entered into their third collaboration, using Rigel s post-genomics combinatorial biology technology to identify drug targets that regulate lung epithelial cell function and other severe respiratory diseases, such as asthma and chronic obstructive pulmonary disease | ND | The initiation of this collaboration triggers an undisclosed cash payment to Rigel, which will also receive milestone and certain royalty payments relating to the development and commercialization of any therapeutics, diagnostics or vaccines resulting from the collaboration; Novartis retains exclusive worldwide rights to develop and market products in those areas relating to targets discovered under the collaboration (8/00) |
| Rosetta Inpharmatics Inc. (RSTA) | Glaxo Wellcome plc (UK; NYSE:GLX) | License agreement/the Rosetta Resolver Expression Data Analysis System | ND | Glaxo licensed the system from Rosetta; terms were ND (12/00) |
| RxKinetix Inc. | Elan Corp. plc (Ireland; NYSE:ELN) | License and research collaboration/development of compound formulations to treat oral mucositis | $2.50 | Alliance takes the form of a structured joint venture into which each company will contribute technology to identify several compounds; initial term is for three years; Elan will make a $2.5M equity investment in RxKinetix and subscribe for a convertible note in the joint venture; R&D will be jointly funded (5/00) |
| Sangamo BioSciences Inc. (SGMO) | Baxter Healthcare Corp. (U.S. subsidiary of Baxter International Inc.; NYSE:BAX) | Research collaboration/development and commercialization of therapeutics for ischemic cardiovascular and peripheral vascular diseases using Sangamo s zinc-finger DNA binding proteins (ZFPs) for activation of vascular endothelial growth factor | $40 | Sangamo may receive up to $40M in research funding, option fees, loans and milestones, and also will receive royalties on any sales; Sangamo will design and advance products through preclinical testing, and Baxter will be responsible for production, clinical trials, approvals and marketing; Baxter also gains a three-year right of first refusal to Sangamo s ZFP cardiovascular product candidates (1/00) |
| Sangamo BioSciences Inc. (SGMO) | Procter & Gamble Pharmaceuticals (unit of The Procter & Gamble Co.; NYSE:PG) | Research collaboration/use of Sangamo s Universal GeneTools | ND | Sangamo will provide specific Universal GeneTools to P&G for internal research and validation (3/00) |
| Sangamo BioSciences Inc. (SGMO) | The R.W. Johnson Pharmaceutical Research Institute (unit of Johnson & Johnson; NYSE:JNJ) | Research collaboration/development of smallmolecule screening platform for the identification of novel therapeutics | ND | Once developed, the small-molecule screening platform will be made available to others in the industry through Sangamo (6/00) |
| Sangamo BioSciences Inc. (SGMO) | Merck & Co. Inc. (NYSE:MRK) | Research agreement/Merck will gain access to Sangamo s Universal GeneTools for internal use | ND | ND (9/00) |
| Sepracor Inc. (SEPR) | Eli Lilly and Co. (NYSE:LLY) | License agreement/modified formulation of fluoxetine, an active ingredient found in Prozac | $90 | Federal Trade Commission concluded review of collaboration under which Sepracor receives an up-front payment of $20M and up to $70M in additional milestones; Sepracor will also receive royalties; Lilly has exclusive worldwide rights for all indications and uses and will be responsible for developmental work on (R)-fluoxetine for all indications and uses, as well as regulatory submis sions, manufacturing, marketing and sales (4/00) |
| Sequenom Inc. (SQNM) | Hitachi Ltd. (NYSE:HIT; Japan) | Distribution and genotyping alliance/Mass ARRAY systems | ND | Hitachi s subsidiary Nissei Sangyo Co. Ltd. will become the exclusive distributor of the systems in Japan (12/00) |
| Serono SA (Switzerland; NYSE:SRA) | Centocor Inc. (unit of Johnson & Johnson; NYSE:JNJ) | License/patents cover ing monoclonal anti bodies to tumor necrosis factor | ND | Centocor will make undisclosed cash payments, but will pay no royalties on sales of products covered by the patents patents; the license is part of a settlement of litigation filed by Serono against Centocor in the District Court of the Hague in the Netherlands (7/00) |
| Serono SA (Switzerland; NYSE:SRA) | Knoll AG (unit of BASF; Germany) | License/patents covering monoclonal antibodies to tumor necrosis factor | ND | Knoll will pay a license fee, milestone payments and royalties on sales (7/00) |
| SignalGene Inc. (Canada; TSE:SGI) | Anapharm Inc. (Canada) | Laboratory service agreement/for the provision of genotyping services | ND | SignalGene will use its technology to characterize the metabolizing status of individuals with regard to orally administered medications (8/00) |
| SkyePharma plc (UK;SKYE) | Pfizer Inc. (NYSE:PFE) | Feasibility contract/use of SkyePharma s Geomatrix oral delivery technology to formulate a Pfizer compound | ND | ND (3/00) |
| SkyePharma plc (UK;SKYE) | Merck KGaA (Germany) | Development collaboration/use of SkyePharma's Geomatrix oral controlled-release technology to formulate a Merck compound | ND | Deal follows proof-of-concept testing; SkyePharma will be responsible for scaling up the process, providing materials for clinical trials and assisting Merck in the compilation of regulatory dossier; SkyPharma will handle manufacturing; Merck receives an exclusive worldwide license and will pay all development costs plus royalties on sales; manufacturing revenues and royalties to SkyePharma are projected at 10%-15% of net sales (5/00) |
| SkyePharma plc (UK;SKYE) | Pfizer Inc. (NYSE:PFE) | Development collaboration/use of SkyePharma's DepoFoam sustainedrelease technology to formulate an undisclosed Pfizer compound | ND | New agreement follows 3/00 feasibilility agreement for use of SkyePharma's Geomatrix delivery system (5/00) |
| Southern BioSystems Inc. | Alcon Pharmaceuticals Ltd. | Development agreement/controlled-release products for certain ophthalmic indications | ND | Alcon will have exclusive access to SBS s microencapsulation technologyfor development of products to treat diseases affecting the back of the eye; SBS will receive product development funding, as well as milestone and royalty payments (12/00) |
| Symyx Technologies Inc. (SMMX) | Aventis Research & Technologies GmbH & Co. KG (France; NYSE:AVE) | Technology collaboration/development of novel instrumentation for high-throughput analysis of pharmaceutical compounds | ND | Companies will share costs under one-year agreement (4/00) |
| Symyx Technologies Inc. (SMMX) | Dow Chemical Co. (NYSE:DOW) | Discovery and license agreement/develop catalysts for manufacturing advanced pharmaceutical intermediates | ND | Dow will fund the research effort, make payments upon technical success and commercialization and have exclusive rights to use the catalysts in its manufacturing process (9/00) |
| Synaptic Pharmaceutical Corp. (SNAP) | Kissei Pharmaceutical Co. Ltd. (Japan) | License agreement and research collaboration/identification and development of drugs that act through receptors that will be identified using Synaptic s genomics technologies | ND | Synaptic will receive a license fee, research funding, milestones and royalties on any drug that emerges from the program; Kissei will have worldwide exclusive rights to use selected receptors from the collaboration to develop, manufacture and market associated drugs (1/00) |
| Synsorb Biotech Inc. (Canada; SYBB) | BCY Ventures Inc. (Canada; CDNX:BCY) | License agreement/Synsorb s technol ogies relating to treatment of complications associated with cystic fibrosis | ND | BCY will issue up to 1.6M common shares to Synsorb, which will represent 30% of all shares of BCY on a fully diluted basis; BCY will issue 0.8M shares upon closing of the the transaction and an additional 0.8M shares upon achievement of mile stones; Synsorb will act as a resource to BCY in developing the technologies |
| Targeted Genetics Corp. (TGEN) | Wyeth-Ayerst, Laboratories (unit of American Home Products Corp.; NYSE:AHP) | Collaboration/develop gene therapy products to treat hemophilia | $80 | TGEN will develop the products with Genetics Institute, a division of Wyeth-Ayerst, a division of AHP; Genetics Institute will pay TGEN $5M up-front, up to $15M for development of the factor VIII product over the next three years, as well as development and commercialization milestones; Genetics Institute also has the option to collaborate on the development of AAV delivery of the gene encoding factor IX to treat hemophilia B, and has agreed to loan TGEN up to $10M to finance manufacturing facility expansions (11/00) |
| Targeted Genetics Corp. (TGEN) | Elan Corp. plc (Ireland; NYSE:ELN) | Strategic partnership to develop and commercialize peptide targeting and drug delivery technologies | ND | Partnership has an initial term of three years and companies will share ownership of the intellecutal property and products developed (11/00) |
| Techniclone Corp. (TCLN) | Merck KGaA (Germany) | Agreement for a segment of Techniclone s Tumor Necrosis Therapy | ND | Techniclone will grant Merck the right to use its TNT antibodies for producing immunocytokines; the agreement involves an undisclosed up-front payment and a royalty on potential sales (10/00) |
| Texas Biotechnology Corp. (AMEX:TBC) | ScheringPlough Corp. (NYSE:SGP) | Research and license agreement/development of VLA-4 antagonists (integrin A4B1) for treatment of asthma | $87 | Schering-Plough gains exclusive rights to develop, manufacture and market all compounds from Texas Biotechnology's library of VLA-4 antagonists and second integrin antagonist; Texas Biotechnology will be responsible for optimizing a lead compound and additional follow-on compounds; Schering-Plough will be responsible for all costs associated with the worldwide product development and commercialization of the compound, and will pay up-front license fee, development milestones and royalties on product sales (7/00) |
| Third Wave Technologies Inc. | Novartis Pharmaceuticals Corp. (unit of Novartis AG; NYSE:NVS) | Development agreement/development of the first high-density panel of 10,000 SNP assays spaced across the human genome; assay panel will use Third Wave s Invader technology to detect single nucleotide polymorphisms released by the SNP Consortium on 5/1/00 | ND | Agreement provides Third Wave with certain rights to diagnostic applications and improvements arising from Novartis use of the Invader technology; Third Wave also has rights to commercialize the panel (6/00) |
| Third Wave Technologies Inc. | SmithKline Beecham Biologicals (unit of SmithKline Beecham plc; UK; NYSE:SBH) | Evaluation/Third Wave s proprietary Invader operating system for use in therapeutic vaccine (Pharmaccines) applications | ND | Third Wave will develop proprietary Invader assays for genotyping and gene expression analysis for use in SBB s Pharmaccines program; SBB will evaluate the assays with an eye toward later using the Invader assay system for reporting of patient results (6/00) |
| Titan Pharmaceuticals Inc. (AMEX:TTP) | Schering AG (Germany) | Development, manufacturing and commercialization agreement/Titan s cell therapy for the treatment of Parkinson s disease | ND | Titan and Schering will collaborate on the manufacturing and clinical development of product; Titan will receive funding for development activities, as well as reimbursement for some prior R&D expenses; Schering will fully fund, and manage in collaboration with Titan, all future clinical trials; Schering receives exclusive worldwide development, manufacturing and commercialization rights, and will pay royalties on any sales; Schering also has the right to make an equity investment in Titan upon initiation of pivotal clinical trials (2/00) |
| Trega Biosciences Inc. (TRGA) | Boehringer Ingelheim International GmbH (Germany) | Research collaboration/custom synthesis of solution phase compound libraries | ND | Trega will generate custom libraries for BI s exclusive use; the initial phase of collaboration is expected to last approximately six months (1/00) |
| Trega Biosciences Inc. (TRGA) | F. HoffmannLa Roche Ltd. (Switzerland) | License/Trega's iDEA predictive model for use in drug discovery programs | ND | Roche licensed the product following successful validation study (7/00) |
| Trega Biosciences Inc. (TRGA) | Aventis Pharma AG (unit of Aventis SA; France; NYSE:AVE) | License agreement/for iDEA predictive model for drug absorption | ND | Aventis will use Trega s absorption module in its drug discovery activities (9/00) |
| Tripos Inc. (TRPS) | Parke-Davis (division of WarnerLambert Co.; now part of Pfizer Inc.; NYSE:PFE) | Research collaboration/development of new informatics methods for high-throughput screening | ND | Three-year, multimillion-dollar agreement under which Tripos and Parke-Davis will jointly design, develop and test screening analysis tools; results of the collaboration eventually will be made available as commercial software products (1/00) |
| Tripos Inc. (TRPS) | Novo Nordisk A/S (Denmark) | Research collaboration/design and develop new software products for pharmaceutical research | ND | Tripos will develop new tools and compare the three-dimensional arrangement of key molecular elements of potential drugs and the receptor sites with which they interact (11/00) |
| Tripos Inc. (TRPS) | Bristol-Myers Squibb Co. (NYSE:BMY) | Collaboration/design and implement a new, integrated research informatics system | ND | Companies will work to develop a new decision support capability to accelerate drug discovery (12/00) |
| Tularik Inc. (TLRK) | Japan Tobacco Inc. (Japan) | Development collaboration/discovery and commercialization of products for the treatment of metabolic diseases | $75 | Tularik will form a wholly owned subsidiary to conduct the research; Japan Tobacco will pay $25M up front and will make research and other payments to Tularik in excess of $50M during the five-year term of the agreement; companies will share expenses and profits equally; Japan Tobacco has the option to buy the subsidiary (5/00) |
| Unigene Laboratories Inc. (OTC BB:UGNE) | Shijiazhuang Pharmaceutical Group Co. Ltd. (China) | Distribution agreement/injectable and nasal calcitonin products for the treatment of osteoporosis | ND | Joint venture will manufacture and distribute injectable and nasal calcitonin products in China and possibly other selected Asian countries in the first phase of the collaboration, SPG will contribute its existing injectable calcitonin license to the joint venture (6/00) |
| Unigene Laboratories Inc. (OTC BB:UGNE) | Pfizer Inc. (NYSE:PFE) | Additional collaboration to existing partnership focused on the oral calcitonin program | ND | The additional collaboration will investigate the feasibility of orally delivering peptides for the treatment of specific endocrine disorders (10/00) |
| Union Biometrica Inc. | Aventis SA (France; NYSE:AVE) | Research and development collaboration/instrumentation and tools | ND | Companies will use the instrumentation and tools for the rapid screening of the nematode Caenorhabditis elegans (12/00) |
| United Therapeutics Corp. (UTHR) | Grupo Ferrer Internacional SA (Italy) | Uniprost, a subcutaneous prostacyclin therapy in Phase III trials for treatment of late-stage pulmonary hypertension | ND | Ferrer gains distribution rights for Spain, France, Germany, Italy, Portugal, Greece and Belgium, as well as Mexico and all countries in Latin America (5/00) |
| United Therapeutics Corp. (UTHR) | Toray Industries (Japan) | License and development agreement/sustainedrelease formulations of the oral prostacyclin Beraprost for all vascular and cardiovascular diseases | $23 | United gains exclusive North American rights to develop and commercialize sustained-release formulations of Beraprost; United will pay Toray $1M plus 200,000 shares of common stock and will grant 500,000 additional shares upon the transfer by Toray to United of sustained-release clinical material; additional payments totaling $0.75M are due to Toray for milestones, along with a daily dosage fee and a variable percent of revenues (6/00) |
| Vertex Pharmaceuticals Inc. (VRTX) | Novartis Pharma AG (NYSE:NVS) | Research collaboration/eight small-molecule drugs directed at targets in the kinase protein family (5/00) | $800 | Novartis will have exclusive worldwide development, manufacturing and marketing rights; Vertex will receive up to $800M in precommercialization payments if all eight compounds are fully developed; Novartis will make an initial payment of $15M, provide research funding of $200M over six years and will provide further license fees, milestones and reimbursements of up to $600M; Vertex will have responsibility for drug discovery and clinical proof-of-concept testing (5/00) |
| Vertex Pharmaceuticals Inc. (VRTX) | Serono SA (Switzerland; (SWX:SEO; NYSE:SRA) | Collaboration/discover, develop and market caspase inhibitors | ND | Vertex could receive up to $95M to support and expand its drug discovery activities; it also will receive milestone payments; the companies expect to select a first drug development candidate in 2001 (12/00) |
| Vical Inc. (VICL) | Aventis Pharma AG (unit of Aventis SA; France; NYSE:AVE) | License agreement/use of naked DNA gene transfer technology to deliver angiogenic growth factor | $1.50 | Aventis Pharma gains rights to Vical's naked DNA gene transfer technology; Vical received an initial payment of $1.5M and could receive milestones and royalties (7/00) |
| Vion Pharmaceuticals Inc. (VION) and EPTTCO Ltd. (UK) | AstraZeneca plc (UK; NYSE:AZN) | Option agreement/anticancer therapies incorporating Vion s TAPET bacterial vector armed with EPTTCO s prodrug activation technology, which uses enzymes to convert inactive prodrugs into cytotoxics | ND | AstraZeneca will evaluate products over nine months; Vion and EPTTCO will handle preclinical testing and AstraZeneca will provide access under its rights to certain prodrugs; AstraZeneca has an exclusive option period to license the specific EPTTCO-armed TAPET vector; Vion and EPTTCO will receive option fees (1/00) |
| ViroLogic Inc. (VLGC) | Merck & Co. Inc. (NYSE:MRK) | Agreement/develop and execute educational programs on the utility of HIV drug-resistance testing for physicians | ND | The companies will conduct a series of physician education meetings to educate physicians about the latest scientific and clinical data in the field (9/00) |
| ViroLogic Inc. (VLGC) | F. HoffmannLa Roche Ltd. (Switzerland) | Research agreement/provide drug resistance testing services | ND | ViroLogic will provide the services in the Phase III clinical program involving the HIV drug, T-20, being co-developed by Roche and Trimeris Inc. (TRMS); ViroLogic will use PhenoSense to determine HIV resistance to approved antiretroviral drugs (10/00) |
| ViroLogic Inc. (VLGC) | Bristol-Myers Squibb Co. (NYSE:BMY) | Agreement/jointly educate physicians about HIV resistance testing and conduct new research | ND | The companies will sponsor a series of continuing medical education programs; they also will collaborate on HIV therapy and resistance studies employing PhenoSense HIV resistance test and including research on BMY s drugs Videx and Zerit (11/00) |
| VistaGen Inc. | Pfizer Inc. (NYSE:PFE) | Collaboration on VistaGen s mouse-derived stem cell-based Genesis Screen technology | ND | Companies will collaborate in a joint development program and evaluation of the utility of the technology as a tool for clinically predictive toxicology screening assays (10/00) |
| Vysis Inc. (VYSI) | F. HoffmannLa Roche Ltd. (Switzerland) | Path Vysion HER-2 breast cancer test kit | ND | Collaboration will allow for the use of the kit outside the U.S. (12/00) |
| Xenogen Corp. | Novartis Research Foundation (unit of Novartis AG; Switzerland; NYSE:NVS) | Licensing agreement/Novartis will gain complete access to Xenogen s suite of technologies for use in preclinical drug development studies at any Novartis site worldwide, including use of Xenogen s real-time in vivo imaging technology | ND | The three-year, multimillion-dollar agreement, with an option for an additional four years, is a result of a successful evaluation license of the technology (8/00) |
| Xenometrix Inc. (OTC BB:XENO) | Pfizer Inc. (NYSE:PFE) | License agreement/Xenometrix s Yeast DEL technology for measuring genotoxic potential of compouds | ND | Pfizer will incorporate Xenometrix s genotoxicology methods into its screening process (3/00) |
| Xenon Genetics Inc. | Warner-Lambert Co. (now part of Pfizer Inc.; NYSE:PFE) | Development agreement/identification of drug targets and lead compounds for treatment of high levels of low-density lipoprotein cholesterol | $58 | Warner acquired exclusive rights to develop and commercialize products and agreed to provide up to C$87M (US$57.75M) in upfront payments, equity purchase, research funding and milestones for the first product commericalized; subsequent products will result in additional payments (5/00) |
| XTL Biopharmaceuticals Ltd. (Israel; LSE:XTL) | Pharming Group NV (the Netherlands; PHAR; AEX:PHAR) | Joint evaluation and co-development/human Lactoferrin | ND | Companies will co-develop recombinant human Lactoferrin as a treatment for hepatitis C; financial terms were ND (11/00) |
| Zonagen Inc. (ZONA) | Wyeth-Ayerst Laboratories (unit of American Home Products Corp.; NYSE:AHP) | Option agreement/collaborate in development of a human immunocontraceptive vaccine | $22.50 | Wyeth-Ayerst has the right to exercise its option for worldwide rights to the zona pelludida contraceptive technology through the payment of an up-front fee and entering into an exclusive license agreement, in which Wyeth-Ayerst will pay for clinical development and marketing and could pay milestones totaling $22.5M, plus royalties (12/00) |
| Notes: This chart does not cover agreements between biotech companies or agricultural agreements. It covers the time between 1/1/00 and 12/31/00; stocks trade on NASDAQ unless otherwise noted. AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; TSE = Toronto Stock Exchang; VSE = Vancouver Stock Exchange. ND = Not disclosed, reported and/or available ** Denotes the date the item ran in BioWorld International. | ||||
